Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Jan 11;31(2):350–367. doi: 10.1007/s00044-021-02836-0

Synthesis and biological evaluation of (20S,24R)-epoxy-dammarane-3β,12β,25-triol derivatives as α-glucosidase and PTP1B inhibitors

Xiao-Tong Yang 1, Tian-Ze Li 1, Chang-An Geng 1, Pei Liu 1, Ji-Jun Chen 1,2,
PMCID: PMC8749348  PMID: 35035203

Abstract

The dammarane triterpenoid (20S,24R)-epoxy-dammarane-3β,12β,25-triol obtained from Cyclocarya paliurus in our previous study showed inhibitory activity on α-glucosidase in vitro with an inhibitory ratio of 32.2% at the concentration of 200 μM. In order to reveal the structure-activity relationships (SARs) and get more active compounds, 42 derivatives of (20S,24R)-epoxy-dammarane-3β,12β,25-triol were synthesized by chemical modification on the hydroxyls (C-3 and C-12), rings A and E, and assayed for their α-glucosidase and PTP1B inhibitory activities. Two compounds (8, 26) increased activity against α-glucosidase, and four compounds (8, 15, 26, 42) significantly inhibited PTP1B. It was noted that compounds 8 and 26 could inhibit both α-glucosidase and PTP1B as dual-target inhibitors with IC50 values of 489.8, 467.7 μM (α-glucosidase) and 319.7, 269.1 μM (PTP1B). Compound 26 was revealed to be a mix-type inhibitor on α-glucosidase and a noncompetitive-type inhibitor on PTP1B based on enzyme kinetic study. Furthermore, compound 42 could selectively inhibited PTP1B as a mix-type inhibitor with IC50 value of 134.9 μM, which was 2.5-fold higher than the positive control, suramin sodium (IC50 339.0 μM), but not inhibit α-glucosidase.

graphic file with name 44_2021_2836_Figa_HTML.jpg

Keywords: (20S,24R)-epoxy-dammarane-3β,12β,25-triol; α-glucosidase inhibitors; PTP1B inhibitors; Enzyme kinetics

Introduction

Diabetes mellitus is a chronic metabolic disease due to that pancreas is unable to produce sufficient insulin or body cannot take full advantage of insulin, its complications including blurred vision, cardiovascular diseases, kidney failure, and organ damage [13]. Diabetes mellitus is mainly divided into type 1 and type 2 diabetes mellitus (T1DM and T2DM), and ~90% of diabetic patients suffers from T2DM. α-Glucosidase and protein tyrosine phosphatase 1B (PTP1B) are two enzymes close related to T2DM. α-Glucosidase is the crucial enzyme for hydrolyzing the 1,4-α-glucosidic linkages of oligosaccharides to release absorbable monosaccharides in small intestine. α-Glucosidase inhibitors can delay the absorption of carbohydrates, and reduce the effect of postprandial hyperglycaemia [46]. Protein tyrosine phosphatase 1B is a key negative regulator of leptin and insulin signaling pathways due to its ability to dephosphorylate and inactivate the insulin receptor [7, 8]. The gene knockout studies indicate PTP1B acts as a major negative regulator of insulin signaling [9, 10]. α-Glucosidase inhibitors are the preferred drugs for controlling postprandial blood glucose, and PTP1B inhibitors can improve insulin sensitivity. Therefore, compounds with α-glucosidase and PTP1B dual inhibition could be more effective and will provide important clues for the development of new antidiabetic candidates.

Natural products are rich sources for searching new antidiabetic agents [11, 12], and the discovery of natural products and their derivatives as potential antidiabetic lead compounds are continuing goals of our laboratory [1321]. The leaves of Cyclocarya paliurus were widely used to treat obesity and diabetes in China. Dammarane-type triterpenoids were characteristic components of C. paliurus, which had shown potent α-glucosidase inhibitory and anti-inflammatory activities [22, 23]. Our previous antidiabetic investigation of C. paliurus indicated (20S,24R)-epoxy-dammarane-3β,12β,25-triol (1) exhibited inhibitory activity on α-glucosidase in vitro with an inhibitory ratio of 32.2% at the concentration of 200 μM. Compound 1 also showed weak inhibition on PTP1B with an inhibitory ratio of 16.4% at concentration of 400 µM. Compound 1 was one of the main constituents of C. paliurus, which provides possibilities for the chemical modification to explore the structure-activity relationships (SARs) and search for new antidiabetic candidates. In current investigation, 42 derivatives of compound 1 were synthesized and assayed for their α-glucosidase and PTP1B inhibitory activities.

Results and discussion

Chemistry

To figure out the roles of hydroxyls at C-3 and C-12 for inhibiting α-glucosidase and PTP1B, a series of derivatives were synthesized as shown in Scheme 1. Compound 1 was treated with anhydrides or carboxylic acids in the presence of N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) to yield compounds 28 with acyl groups at C-3, compounds 915 with acyl groups at C-12 and di-esterified products 1621. Oxidation of compound 1 using pyridinium chlorochromate (PCC) afforded ketones 2224 with different oxidation location at C-3 and C-12, while compound 22 could be selectively obtained in 70% yield via Oppenauer oxidation [24]. When compound 22 and hydroxylamine hydrochloride were heated in the presence of sodium acetate trihydrate, the oxime derivative 25 was afforded in 93% yield [25]. From compound 23, phthalic derivative 26 was provided in 76% yield by esterification with o-phthalic anhydride.

Scheme 1.

Scheme 1

Reagents and conditions: (a) DCC, DMAP, appropriate carboxylic acid, dry DCM, 0 °C – r.t., 59 % (3, 10, 17, 19% + 23% + 16%), 43% (4, 11, 18, 16% + 13% + 14%), 53% (5, 12, 19, 17% + 30% + 6%), 42% (6, 13, 20, 13% + 23% + 6%), 37% (7, 14, 21, 13% + 16% + 8%) or o-phthalic anhydride, pyridine, DMAP, 80 °C, 38% (8, 15, 10% + 28%) or Ac2O, pyridine, r.t., 68% (2, 9, 16, 20% + 24% + 24%); b Al(Oi-Pr)3, acetone, toluene, reflux, 70% (22) or PCC, DCM, r.t., 68% (22, 23, 24, 18% + 20% + 30%); c NH2OH•HCl, CH3COONa•3H2O, EtOH-H2O (10:1), reflux, 93%; d o-phthalic anhydride, pyridine, DMAP, 80 °C, 76%

Next, different functionalities were introduced on ring A (Scheme 2). The formylation of compound 22 with ethyl formate in the presence of Na gave compound 27 [26], and subsequent reduction with sodium borohydride delivered 2-hydroxymethyl derivative 28. Treatment of compound 27 with hydroxylamine hydrochloride provided isoxazole 29 in good yield [27]. Exposure of compound 22 to Baeyer–Villiger conditions delivered ring expansion product 30 [28, 29], which was further transformed into ring A opening derivatives 31 and 32 by hydrolysis or reduction of ester [30].

Scheme 2.

Scheme 2

Reagents and conditions: (a) HCOOEt, Na, Et2O, reflux, 76%; b NaBH4, MeOH, r.t., 69%; c NH2OH•HCl, EtOH-H2O (10:1), reflux, 56%; d m-CPBA, NaHCO3, DCM, r.t., 71%; e 10% NaOH aqueous, MeOH, reflux, 82%; f LiAlH4, dry THF, r.t.−50 °C, 50%

Oxidative cleavage of compound 16 with PCC and subsequent hydrolysis with NaOH resulted in lactone 33, and reduction of the lactone with LiAlH4 afforded ring-opening product 34. To get more ring-opening products and study the influence of substituted tetrahydrofuran side chain on the activity, nine derivatives with different oxidation location on the side chain were synthesized from naturally abundant dammarane triterpenoid, 20(S)-PPD. Alkene hydrogenation of compound 35 with H2 and Pd/C gave derivative 36. A protection/dihydroxylation/deprotection sequence produced compounds 38 and 39 as a 1.2:1 mixture of diastereomers, and oxidative cleavage of the diol using NaIO4 delivered hemiacetal 40. Pd/C-catalyzed regioselective hydrogenation of compound 37 followed by one pot dehydration and deacetylation afforded compounds 42 and 43 Scheme 3. Compound 44 was synthesized via Lemieux-Johnson oxidation in 61% yield.

Scheme 3.

Scheme 3

Reagents and conditions: (a) (i) PCC, DCM, 40 °C, 54%; (ii) 10% NaOH aqueous, MeOH, reflux, 91%; b LiAlH4, dry THF, r.t.−50 °C, 35%; c Pd/C, H2, EtOH, r.t, 80%; d Ac2O, pyridine, DMAP, r.t., 86%; e (i) KMnO4, EtOH-H2O (15:1), −40 °C; (ii) 10% NaOH aqueous, MeOH, reflux, 38 (52%), 39 (42%); f NaIO4, MeOH, H2O, r.t., 82%; g Pd/C, H2, r.t., 87%; h (i) POCl3, pyridine, 40 °C; (ii) 10% NaOH aqueous, MeOH, reflux, 42 (16%), 43 (43%); (i) OsO4, NaIO4, MeOH-H2O, r.t., 61%

Taking compound 26 as an example, the structural characterization of the synthesized compounds was explained as follows. Compound 26 had a molecular formula of C38H54O7 deduced by the (-)-HRESIMS ion at m/z 621.3787 [M-H] (Calcd. for 621.3797). The 1H NMR data of compound 26 displayed signals of eight singlet methyl groups at δH 1.23 (3H, s), 1.20 (3H, s), 1.19 (3H, s), 1.13 (3H, s), 1.10 (3H, s), 1.08 (3H, s), 0.94 (3H, s) and 0.89 (3H, s), two oxygenated methines at δH 4.92 (1H, m, H-3) and 3.70 (1H, t, J = 7.4 Hz, H-24), and four aromatic hydrogens at δH 7.90 (1H, m, H-4′), 7.59 (3H, m, H-5′, H-6’, H-7′); the 13C NMR (DEPT) spectrum revealed 38 carbon resonances attributable to three carbonyls (δC 212.1, 168.2, 168.2), four unsubstituted aryl carbons (δC 129.5, 130.7, 131.1 and 129.1), two substituted aryl carbons (δC 133.5, 133.5), eight methyls, seven sp3 methines (three oxygenated, δC 80.3, 71.4, 83.4), and six sp3 quaternary carbons (two oxygenated, δC 86.1, 71.6). From the above characteristic signals, the structure of compound 26 was concluded.

Biology

The inhibitory activities of all the synthesized derivatives on α-glucosidase and PTP1B were tested with acarbose and suramin sodium as the positive control, respectively. (Table 1). The inhibitory ratio of derivatives on α-glucosidase was primarily tested at the concentration of 200 μM. For compounds 28 with different acyloxy group at C-3, only phthalic derivative 3 maintained activity. Among C-12 esterification derivatives 915, acetylation product 9 exhibited the similar inhibitory potency with that of compound 1. Di-esterification products 1621 lost suppressant properties on α-glucosidase. When the hydroxyl group at C-3 was oxidized to be carbonyl group, compound 10 showed better inhibitory ratio than that of compound 1 (46.6% vs 32.2%). Compounds 2732 modified on ring A were inactive, which indicated that ring A of compound 1 is essential for α-glucosidase inhibitory effects. For compounds 3344 with different oxidation location on the side chain, compounds 34 and 35 maintained activity at the concentration of 200 μM.

Table 1.

α-Glucosidase and PTP1B inhibitory activities of derivatives 144a

Compounds Inhibitory ratio (%)b Compounds Inhibitory ratio (%)b
α-Glucosidase PTP1B α-Glucosidase PTP1B
1 32.2 16.4 23 46.6 15.1
2 6.7 13.2 24 5.3 3.7
3 11.9 22.3 25 20.0
4 20.3 9.6 26 26.5 79.2
5 11.2 19.7 27 8.5
6 8.6 14.4 28 9.6
7 21.0 26.0 29 20.2
8 31.9 62.8 30 12.8
9 38.7 17.8 31 9.4
10 10.8 15.3 32
11 4.8 21.3 33 6.6
12 9.8 13.7 34 36.5 16.6
13 21.2 14.8 35 36.5 15.5
14 5.7 20.2 36 2.3 15.7
15 0.8 58.8 37 10.8
16 5.9 4.6 38 12.3 21.2
17 c 9.4 39 15.0 15.4
18 6.7 23.6 40
19 18.0 41 8.5
20 3.3 16.6 42 73.6
21 6.5 20.6 43 5.4
22 8.6 1.3 44 3.8

aData were expressed as means of two tests

bThe tested concentrations were 200 µM (α-glucosidase) and 400 µM (PTP1B)

c“‒” means no activity

For PTP1B, the phthalate compounds 8, 15 and 26 increased 3.8, 3.6 and 4.8-folds of inhibitory activity at the concentration of 400 μM, suggesting the additional carboxyl groups were favorable. For derivatives 2744 with different functionalities on ring A and the side chain, compound 42 exhibited activity with an inhibitory ratio of 73.6%, which was 4.5 times stronger than that of compound 1. Different with its double bond positional isomers 42, derivative 43 was almost inactive, which indicated that the location of the double bond on the side chain had significant influence on PTP1B inhibitory effects.

Dose-response relationships of the active compounds were further studied to measure their IC50 values (Table 2). Interestingly, compounds 8 and 26 containing a phthalic acid moiety at C-3 showed inhibitory activity on both enzymes with IC50 values of 489.8, 467.7 μM (α-glucosidase) and 319.7, 269.1 μM (PTP1B), which were superior to compound 1 (IC50 values higher than 800 μM). When the phthalic acid was located at C-12, the resulted compound 15 was only active against PTP1B with an IC50 value of 341.7 μM; and all the three phthalate derivatives showed the similar inhibitory activity and compound 42 showed about 2.5-fold higher by comparison with the positive control suramin sodium.

Table 2.

α-Glucosidase and PTP1B inhibitory activities of the selected derivativesa

Compounds IC50 (µM)
α-Glucosidase PTP1B
1 >800 >800
8 489.8 319.7
15 341.7
26 467.7 269.1
42 134.9
Acarboseb 0.018
Suramin sodiumc 339.0

aData were expressed as means of two tests

bAcarbose was used as the positive control against α-glucosidase

cSuramin sodium was used as the positive control against PTP1B

Compound 26 showed activity against both α-glucosidase and PTP1B with IC50 values of 467.7 and 269.1 µM, respectively. Enzyme kinetic studies by Lineweaver–Burk plot and Dixon plot showed the lines of compound 26 intersected at the third quadrant and the Vmax and Ki values were decreased with the increase of concentration (Fig. 1A), indicating compound 26 was a mixed-type inhibitor against α-glucosidase with Ki value of 414.4 μM. Meanwhile, the line of compound 26 intersected on the x-axis (Fig. 1B), indicating it was a noncompetitive-type inhibitor against PTP1B (Ki value: 110.7 μM). Compound 42 showed the highest activity against PTP1B with an IC50 value of 134.9 µM, and enzyme kinetics study manifested it was a mixed-type inhibitor with a Ki value of 139.2 μM.

Fig. 1.

Fig. 1

Lineweaver–Burk and Dixon plots of compound 26 against α-glucosidase (A/a), PTP1B (B/b) and compound 42 against PTP1B(C/c)

Conclusions

In summary, 42 derivatives of (20S,24R)-epoxy-dammarane-3β,12β,25-triol were synthesized and assayed for their α-glucosidase and PTP1B inhibitory activities. Two compounds (8, 26) increased activity on α-glucosidase. Four compounds (8, 15, 26, 42) were active on PTP1B, of which compound 42 showed the highest activity with the IC50 value superior to suramin sodium. Especially, phthalic derivatives 8 and 26 showed inhibitory activity on both α-glucosidase and PTP1B. Enzyme kinetic study consolidated that compound 26 was a mix-type inhibitor against α-glucosidase and a noncompetitive-type inhibitor against PTP1B with Ki values of 414.4 μM and 110.7 μM, respectively. The primary SARs were concluded as: (a) ring A is crucial for maintaining α-glucosidase and PPT1B inhibitory activity; (b) the incorporation of carboxyl groups at C-3 is favorable. These results provide valuable clues for the discovery of PTP1B and α-glucosidase dual inhibitors.

Experimental

Chemistry

General

All reagents and solvents were obtained from commercial supplies and used without further purification. 1H NMR and 13C NMR spectra were tested on Avance III HD 400 (Bruker, Germany), Avance III 500 (Bruker, Germany) and Avance III 600 (Bruker, Germany) spectrometers with TMS as the internal standard. (20S,24R)-Epoxy- dammarane-3β,12β,25-triol was isolated from Cyclocarya paliurus. All synthetic compounds were purified by column chromatography on silica gel (200–300 mesh, Qingdao Makall Group Co., Ltd., Qingdao, China).

Synthesis

General procedure for the synthesis of compounds 2, 9 and 16

To a solution of (20S,24R)-epoxy-dammarane-3β,12β,25-triol (56.0 mg, 0.12 mmol) in pyridine (1.2 mL) was added acetic anhydride (1.2 mL) at room temperature, and the mixture was stirred at room temperature for 12 h. The reaction mixture was then diluted with EtOAc and washed with 5% HCl aqueous solution. The aqueous phase was extracted with EtOAc, and the combined organic phases were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 10:90) to give compounds 2, 9, and 16.

(20S,24R)-epoxy-3β-acetyl-dammarane-12β,25-diol (2)

White powder, 20% yield, 1H NMR (500 MHz, CDCl3) δ 4.60 (1H, m, H-3), 3.92 (1H, td, J = 10.5, 5.5 Hz, H-12), 3.73 (1H, t, J = 7.5 Hz, H-24), 2.08 (3H, s, H-2′), 1.21 (3H, s), 1.13 (3H, s), 1.12 (3H, s), 1.06 (3H, s), 0.96 (3H, s), 0.95 (3H, s), 0.91 (3H, s), 0.84 (3H, s); 13C NMR (125 MHz, CDCl3) δ 35.8 (CH2, C-1), 23.0 (CH2, C-2), 78.2 (CH, C-3), 37.0 (C, C-4), 50.6 (CH, C-5), 17.9 (CH2, C-6), 36.0 (CH2, C-7), 41.0 (C, C-8), 55.5 (CH, C-9), 39.1 (C, C-10), 39.8 (CH2, C-11), 71.2 (CH, C-12), 41.3 (CH, C-13), 50.0 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.4 (CH, C-17), 16.8 (CH3, C-18), 16.5 (CH3, C-19), 86.0 (C, C-20), 23.3 (CH3, C-21), 36.3 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.4 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.4 (CH3, C-28), 21.5 (CH3, C-29), 16.5 (CH3, C-30), 170.9 (CO, C-1′), 21.9 (CH3, C-2′); HRMS (ESI) m/z calcd for C33H55O7 563.3953, found 563.3958 (M + HCOO).

(20S,24R)-epoxy-12β-acetyl-dammarane-3β,25-diol (9)

White powder, 24% yield; 1H NMR (500 MHz, CDCl3) δ 3.36 (1H, m, H-3), 5.11 (1H, td, J = 10.7, 5.5 Hz, H-12), 3.70 (1H, t, J = 7.4 Hz, H-24), 1.20 (3H, s), 1.11 (3H, s), 1.10 (3H, s), 0.99 (3H, s), 0.96 (3H, s), 0.94 (3H, s), 0.94 (3H, s), 0.84 (3H, s), 1.96 (3H, s, H-2′); 13C NMR (125 MHz, CDCl3) δ 34.9 (CH2, C-1), 25.5 (CH2, C-2), 75.8 (CH, C-3), 37.9 (C, C-4), 49.1 (CH, C-5), 18.0 (CH2, C-6), 35.0 (CH2, C-7), 41.3 (C, C-8), 52.6 (CH, C-9), 39.0 (C, C-10), 34.5 (CH2, C-11), 73.2 (CH, C-12), 40.6 (CH, C-13), 49.8 (C, C-14), 31.1 (CH2, C-15), 26.0 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.9 (CH3, C-21), 35.7 (CH2, C-22), 26.0 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.3 (CH3, C-30), 170.4 (CO, C-1’), 22.1 (CH3, C-2′); HRMS (ESI+) m/z calcd for C32H54O5Na 541.3863, found 541.3838 (M + Na+).

(20S,24R) -epoxy-3β,12β-diacetyl-dammarane-25-ol (16)

White powder, 24% yield; 1H NMR (500 MHz, CDCl3) δ 4.57 (1H, m, H-3), 5.12 (1H, td, J = 10.5, 5.5 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.24 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.00 (3H, s), 0.98 (3H, s), 0.97 (3H, s), 0.88 (3H, s), 0.84 (3H, s), 1.96 (3H, s, H-2′), 2.09 (3H, s, H-2″); 13C NMR (125 MHz, CDCl3) δ 34.6 (CH2, C-1), 23.0 (CH2, C-2), 78.1 (CH, C-3), 37.0 (C, C-4), 50.2 (CH, C-5), 17.9 (CH2, C-6), 35.6 (CH2, C-7), 40.6 (C, C-8), 52.5 (CH, C-9), 38.8 (C, C-10), 34.8 (CH2, C-11), 73.3 (CH, C-12), 41.3 (CH, C-13), 49.8 (C, C-14), 31.2 (CH2, C-15), 25.9 (CH2, C-16), 49.0 (CH, C-17), 16.7 (CH3, C-18), 16.7 (CH3, C-19), 86.1 (C, C-20), 24.1 (CH3, C-21), 35.6 (CH2, C-22), 26.1 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.4 (CH3, C-28), 22.1 (CH3, C-29), 16.4 (CH3, C-30), 170.9 (CO, C-1′), 21.9 (CH3, C-2′), 170.3 (CO, C-1″), 21.5 (CH3, C-2″); HRMS (ESI+) m/z calcd for C34H56O6Na 583.3969, found 583.4012 (M + Na+).

General procedure for the synthesis of compounds 3–7, 10–14, 17–21

To a solution of appropriate carboxylic acid (0.06 mmol) in anhydrous dichloromethane (2 mL) was added DCC (27.3 mg, 0.132 mmol) and DMAP (1.2 mg, 0.01 mmol) at 0 °C. After stirred for 10 min, (20 S,24 R)-epoxy-dammarane-3β,12β,25-triol (25.0 mg, 0.05 mmol) was added. The mixture was then warmed to room temperature and stirred until the reaction completed (monitored by TLC). After completion of the reaction, placed the flask in the freezer at −10 °C for 6 h, and the suspension was filtered, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 6:94) to give target compounds.

(20S,24R)-epoxy-3β-benzoyl-dammarane-12β,25-diol (3)

Light yellow powder, 19% yield; 1H NMR (500 MHz, CDCl3) δ 4.86 (1H, m, H-3), 3.99 (1H, m, H-12), 3.73 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.13 (3H, s), 1.12 (3H, s), 1.00 (3H, s), 0.99 (3H, s), 0.98 (3H, s), 0.94 (3H, s), 8.07 (2H, m, H-3′, H-7′), 7.47 (2H, m, H-4′, H-6′), 7.57 (1H, m, H-5′); 13C NMR (125 MHz, CDCl3) δ 36.4 (CH2, C-1), 23.1 (CH2, C-2), 79.0 (CH, C-3), 37.5 (C, C-4), 51.3 (CH, C-5), 18.0 (CH2, C-6), 36.0 (CH2, C-7), 41.1 (C, C-8), 55.8 (CH, C-9), 39.2 (C, C-10), 39.8 (CH2, C-11), 71.3 (CH, C-12), 41.4 (CH, C-13), 50.0 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.4 (CH, C-17), 16.8 (CH3, C-18), 16.5 (CH3, C-19), 85.9 (C, C-20), 23.2 (CH3, C-21), 36.4 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.4 (C, C-25), 27.5 (CH3, C-26), 24.3 (CH3, C-27), 28.7 (CH3, C-28), 22.0 (CH3, C-29), 16.5 (CH3, C-30), 166.1 (CO, C-1′), 131.2 (C, C-2′), 130.0 (CH, C-3′, C-7′), 128.4 (CH, C-4′, C-6′), 132.7 (CH, C-5′); HRMS (ESI) m/z calcd for C38H57O7 625.4110, found 625.4097 (M + HCOO).

(20S,24R)-epoxy-3β-nicotinoyl-dammarane-12β,25-diol (4)

Light yellow powder, 16% yield; 1H NMR (500 MHz, CDCl3) δ 4.89 (1H, m, H-3), 3.99 (1H, m, H-12), 3.73 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.13 (3H, s), 1.12 (3H, s), 1.00 (3H, s), 0.99 (3H, s), 0.97 (3H, s), 0.94 (3H, s), 9.28 (1H, dd, J = 2.2, 0.9 Hz, H-3′), 8.79 (1H, dd, J = 4.9, 2.0 Hz, H-4′), 7.43 (1H, ddd, J = 7.9, 4.9, 0.9 Hz, H-5′), 8.32 (1H, dt, J = 7.9, 2.0 Hz, H-6′); 13C NMR (125 MHz, CDCl3) δ 36.3 (CH2, C-1), 23.1 (CH2, C-2), 79.8 (CH, C-3), 37.5 (C, C-4), 51.4 (CH, C-5), 18.0 (CH2, C-6), 36.0 (CH2, C-7), 41.0 (C, C-8), 55.8 (CH, C-9), 39.2 (C, C-10), 39.9 (CH2, C-11), 71.2 (CH, C-12), 41.4 (CH, C-13), 50.0 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.3 (C, C-17), 16.8 (CH3, C-18), 16.6 (CH3, C-19), 85.9 (C, C-20), 23.4 (CH3, C-21), 36.3 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.4 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.7 (CH3, C-28), 22.0 (CH3, C-29), 16.5 (CH3, C-30), 164.8 (CO, C-1′), 126.9 (C, C-2′), 150.8 (CH, C-3′), 153.2 (CH, C-4′), 123.4 (CH, C-5′), 137.2 (CH, C-6′); HRMS (ESI+) m/z calcd for C36H56NO5 582.4153, found 582.4113 (M + H+).

(20S,24R)-epoxy-3β-furoyl-dammarane-12β,25-diol (5)

Light yellow powder, 17% yield; 1H NMR (500 MHz, CDCl3) δ 4.82 (1H, m, H-3), 3.98 (1H, m, H-12), 3.39 (1H, t, J = 7.3 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.10 (3H, s), 0.98 (3H, s), 0.97 (3H, s), 0.97 (3H, s), 0.92 (3H, s), 7.15 (1H, dd, J = 3.4, 0.9 Hz, H-3′), 6.52 (1H, dd, J = 3.4, 1.8 Hz, H-4′), 7.59 (1H, dd, J = 1.8, 0.9 Hz, H-5′); 13C NMR (125 MHz, CDCl3) δ 36.3 (CH2, C-1), 23.1 (CH2, C-2), 79.1 (CH, C-3), 37.4 (C, C-4), 51.0 (CH, C-5), 18.0 (CH2, C-6), 35.9 (CH2, C-7), 41.0 (C, C-8), 55.7 (CH, C-9), 39.1 (C, C-10), 39.8 (CH2, C-11), 71.3 (CH, C-12), 41.4 (CH, C-13), 50.0 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.4 (CH, C-17), 16.8 (CH3, C-18), 16.5 (CH3, C-19), 86.0 (C, C-20), 23.4 (CH3, C-21), 36.2 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.6 (CH3, C-28), 21.9 (CH3, C-29), 16.5 (CH3, C-30), 158.5 (CO, C-1′), 145.3 (C, C-2′), 117.2 (CH, C-3′), 111.7 (CH, C-4’), 146.1 (CH, C-5′); HRMS (ESI+) m/z calcd for C35H54O6Na 593.3813, found 593.3778 (M + Na+).

(20S,24R)-epoxy-3β-thenoyl-dammarane-12β,25-diol (6)

Light yellow powder, 13% yield; 1H NMR (500 MHz, CDCl3) δ 4.78 (1H, m, H-3), 3.96 (1H, m, H-12), 3.72 (1H, t, J = 7.4 Hz, H-24), 1.20 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.10 (3H, s), 0.98 (3H, s), 0.97 (3H, s), 0.97 (3H, s), 0.93 (3H, s), 7.80 (1H, dd, J = 3.8, 1.3 Hz, H-3’), 7.12 (1H, dd, J = 5.0, 3.8 Hz, H-4′), 7.55 (1H, dd, J = 5.0, 1.3 Hz, H-5′); 13C NMR (125 MHz, CDCl3) δ 36.3 (CH2, C-1), 23.0 (CH2, C-2), 79.4 (CH, C-3), 37.4 (C, C-4), 51.0 (CH, C-5), 17.9 (CH2, C-6), 36.0 (CH2, C-7), 41.0 (C, C-8), 55.7 (CH, C-9), 39.1 (C, C-10), 39.7 (CH2, C-11), 71.3 (CH, C-12), 41.4 (CH, C-13), 49.9 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.4 (CH, C-17), 16.8 (CH3, C-18), 16.5 (CH3, C-19), 86.0 (C, C-20), 23.3 (CH3, C-21), 36.2 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.7 (CH3, C-28), 21.8 (CH3, C-29), 16.4 (CH3, C-30), 161.8 (CO, C-1′), 134.8 (C, C-2′), 132.9 (CH, C-3′), 127.9 (CH, C-4′), 132.0 (CH, C-5′); HRMS (ESI+) m/z calcd for C35H54O5SNa 609.3584, found 609.3606 (M + Na+).

(20S,24R)-epoxy-3β-cinnamoyl-dammarane-12β,25-diol (7)

Light yellow powder, 13% yield; 1H NMR (500 MHz, CDCl3) δ 4.74 (1H, m, H-3), 3.98 (1H, m, H-12), 3.73 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.09 (3H, s), 0.99 (3H, s), 0.99 (3H, s), 0.96 (3H, s), 0.90 (3H, s), 6.51 (1H, d, J = 16.0 Hz, H-2’), 7.68 (1H, d, J = 16.0 Hz, H-3′), 7.56 (2H, m, H-5′, H-9′), 7.39 (3H, m, H-6′, H-7′, H-8′); 13C NMR (125 MHz, CDCl3) δ 36.2 (CH2, C-1), 23.3 (CH2, C-2), 78.4 (CH, C-3), 37.3 (C, C-4), 50.9 (CH, C-5), 17.9 (CH2, C-6), 35.9 (CH2, C-7), 41.1 (C, C-8), 55.7 (CH, C-9), 39.2 (C, C-10), 39.8 (CH2, C-11), 71.3 (CH, C-12), 41.4 (CH, C-13), 50.0 (C, C-14), 31.1 (CH2, C-15), 25.7 (CH2, C-16), 49.4 (CH, C-17), 16.8 (CH3, C-18), 16.6 (CH3, C-19), 86.0 (C, C-20), 23.1 (CH3, C-21), 36.4 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.5 (CH3, C-26), 24.3 (CH3, C-27), 28.6 (CH3, C-28), 22.0 (CH3, C-29), 16.5 (CH3, C-30), 166.7 (CO, C-1′), 119.0 (CH, C-2′), 144.3 (CH, C-3′), 134.6 (C, C-4′), 128.1 (CH, C-5′, C-9′), 128.9 (CH, C-6′, C-8′), 130.1 (CH, C-7′); HRMS (ESI) m/z calcd for C40H59O7 651.4266, found 651.4265 (M + HCOO).

(20S,24R)-epoxy-12β-benzoyl-dammarane-3β,25-diol (10)

White powder, 23% yield; 1H NMR (500 MHz, CDCl3) δ 3.34 (1H, m, H-3), 5.44 (1H, td, J = 10.8, 5.5 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.20 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.07 (3H, s), 1.00 (3H, s), 0.99 (3H, s), 0.96 (3H, s), 0.83 (3H, s), 8.03 (2H, m, H-3′, H-7′), 7.42 (2H, m, H-4′, H-6′), 7.55 (1H, m, H-5′); 13C NMR (125 MHz, CDCl3) δ 35.1 (CH2, C-1), 25.4 (CH2, C-2), 75.9 (CH, C-3), 37.9 (C, C-4), 49.1 (CH, C-5), 18.0 (CH2, C-6), 35.3 (CH2, C-7), 41.4 (C, C-8), 52.8 (CH, C-9), 39.0 (C, C-10), 34.6 (CH2, C-11), 74.0 (CH, C-12), 40.7 (CH, C-13), 49.9 (C, C-14), 31.2 (CH2, C-15), 29.7 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.8 (CH3, C-21), 35.8 (CH2, C-22), 26.0 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 165.7 (CO, C-1′), 131.0 (C, C-2′), 129.8 (CH, C-3′, C-7′), 128.3 (CH, C-4′, C-6′), 132.8 (CH, C-5′); HRMS (ESI+) m/z calcd for C37H56O5Na 603.4020, found 603.4041 (M + Na+).

(20S,24R)-epoxy-12β-nicotinoyl-dammarane-3β,25-diol (11)

White powder, 13% yield; 1H NMR (500 MHz, CDCl3) δ 3.34 (1H, m, H-3), 5.47 (1H, td, J = 10.5, 5.5 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.20 (3H, s), 1.13 (3H, s), 1.12 (3H, s), 1.07 (3H, s), 1.01 (3H, s), 1.00 (3H, s), 0.96 (3H, s), 0.83 (3H, s), 9.21 (1H, d, J = 2.1 Hz, H-3’), 8.76 (1H, dd, J = 4.8, 1.8 Hz, H-4′), 7.37 (1H, dd, J = 7.9, 4.8 Hz, H-5′), 8.27 (1H, dt, J = 7.9, 2.0 Hz, H-6′); 13C NMR (125 MHz, CDCl3) δ 35.0 (CH2, C-1), 25.4 (CH2, C-2), 75.7 (CH, C-3), 37.9 (C, C-4), 49.0 (CH, C-5), 18.1 (CH2, C-6), 35.4 (CH2, C-7), 41.5 (C, C-8), 52.7 (CH, C-9), 39.0 (C, C-10), 34.7 (CH2, C-11), 74.7 (CH, C-12), 40.6 (CH, C-13), 49.9 (C, C-14), 31.2 (CH2, C-15), 29.7 (CH2, C-16), 48.9 (CH, C-17), 16.9 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 24.0 (CH3, C-21), 35.7 (CH2, C-22), 25.9 (CH2, C-23), 83.2 (CH, C-24), 71.3 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 164.5 (CO, C-1′), 126.7 (C, C-2′), 151.2 (CH, C-3′), 153.3 (CH, C-4′), 123.3 (CH, C-5′), 137.2 (CH, C-6′); HRMS (ESI+) m/z calcd for C36H56NO5 582.4153, found 582.4129 (M + H+).

(20S,24R)-epoxy-12β-furoyl-dammarane-3β,25-diol (12)

White powder, 30% yield; 1H NMR (500 MHz, CDCl3) δ 3.35 (1H, m, H-3), 5.37 (1H, td, J = 10.8, 5.5 Hz, H-12), 3.70 (1H, t, J = 7.4 Hz, H-24), 1.20 (3H, s), 1.12 (3H, s), 1.11 (3H, s), 1.04 (3H, s), 0.98 (3H, s), 0.98 (3H, s), 0.95 (3H, s), 0.84 (3H, s), 7.08 (1H, dd, J = 3.5, 0.8 Hz, H-3′), 6.47 (1H, dd, J = 3.5, 1.7 Hz, H-4′), 7.56 (1H, d, J = 1.7 Hz, H-5′); 13C NMR (125 MHz, CDCl3) δ 35.0 (CH2, C-1), 25.5 (CH2, C-2), 75.8 (CH, C-3), 37.9 (C, C-4), 49.2 (CH, C-5), 18.0 (CH2, C-6), 35.5 (CH2, C-7), 41.4 (C, C-8), 52.7 (CH, C-9), 39.0 (C, C-10), 34.5 (CH2, C-11), 74.0 (CH, C-12), 40.7 (CH, C-13), 49.9 (C, C-14), 31.1 (CH2, C-15), 25.8 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.0 (C, C-20), 23.6 (CH3, C-21), 35.8 (CH2, C-22), 26.0 (CH2, C-23), 83.5 (CH, C-24), 71.3 (C, C-25), 27.4 (CH3, C-26), 24.8 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 158.1 (CO, C-1’), 145.4 (C, C-2′), 117.8 (CH, C-3′), 111.8 (CH, C-4′), 146.3 (CH, C-5′); HRMS (ESI+) m/z calcd for C35H54O6Na 593.3813, found 593.3785 (M + Na+).

(20S,24R)-epoxy-12β-thenoyl-dammarane-3β,25-diol (13)

White powder, 23% yield; 1H NMR (500 MHz, CDCl3) δ 3.35 (1H, m, H-3), 5.37 (1H, td, J = 10.8, 5.5 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.12 (3H, s),1.11 (3H, s), 1.05 (3H, s), 1.00 (3H, s), 1.00 (3H, s), 0.96 (3H, s), 0.84 (3H, s), 7.75 (1H, dd, J = 3.7, 1.3 Hz, H-3′), 7.0 (1H, dd, J = 5.0, 3.7 Hz, H-4′), 7.53 (1H, dd, J = 5.0, 1.3 Hz, H-5′); 13C NMR (125 MHz, CDCl3) δ 35.2 (CH2, C-1), 25.5 (CH2, C-2), 75.8 (CH, C-3), 37.9 (C, C-4), 49.1 (CH, C-5), 18.0 (CH2, C-6), 35.4 (CH2, C-7), 41.4 (C, C-8), 52.7 (CH, C-9), 39.0 (C, C-10), 34.5 (CH2, C-11), 74.3 (CH, C-12), 40.7 (CH, C-13), 49.9 (C, C-14), 31.1 (CH2, C-15), 25.6 (CH2, C-16), 48.9 (CH, C-17), 16.8 (CH3, C-18), 16.7 (CH3, C-19), 86.0 (C, C-20), 23.8 (CH3, C-21), 35.8 (CH2, C-22), 26.0 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.3 (CH3, C-26), 25.0 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 161.5 (CO, C-1′), 135.0 (C, C-2′), 133.3 (CH, C-3′), 127.7 (CH, C-4′), 132.4 (CH, C-5′); HRMS (ESI+) m/z calcd for C35H54O5SNa 609.3584, found 609.3589 (M + Na+).

(20S,24R)-epoxy-12β-cinnamoyl-dammarane-3β,25-diol (14)

White powder, 16% yield; 1H NMR (500 MHz, CDCl3) δ 3.36 (1H, m, H-3), 5.28 (1H, td, J = 10.7, 5.4 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.12 (3H, s), 1.11 (3H, s), 1.04 (3H, s), 0.99 (3H, s), 0.98 (3H, s), 0.95 (3H, s), 0.84 (3H, s), 6.36 (1H, d, J = 16.0 Hz, H-2′), 7.63 (1H, d, J = 16.0 Hz, H-3′), 7.51 (2H, m, H-5′, H-9′), 7.37 (3H, m, H-6′, H-7′, H-8′); 13C NMR (125 MHz, CDCl3) δ 35.1 (CH2, C-1), 25.6 (CH2, C-2), 75.9 (CH, C-3), 37.9 (C, C-4), 49.1 (CH, C-5), 18.1 (CH2, C-6), 35.1 (CH2, C-7), 41.4 (C, C-8), 52.8 (CH, C-9), 39.1 (C, C-10), 34.7 (CH2, C-11), 73.4 (CH, C-12), 40.7 (CH, C-13), 49.9 (C, C-14), 31.2 (CH2, C-15), 26.9 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.9 (CH3, C-21), 35.8 (CH2, C-22), 26.0 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 166.2 (CO, C-1′), 119.1 (CH, C-2′), 144.6 (CH, C-3′), 134.5 (C, C-4′), 128.1 (CH, C-5′, C-9′), 128.9 (CH, C-6′, C-8′), 130.2 (CH, C-7′); HRMS (ESI+) m/z calcd for C39H58O5Na 629.4176, found 629.4166 (M + Na+).

(20S,24R)-epoxy-3β,12β-dibenzoyl-dammarane-25-ol (17)

Light yellow powder, 16% yield; 1H NMR (500 MHz, CDCl3) δ 4.82 (1H, m, H-3), 5.47 (1H, td, J = 10.8, 5.2 Hz, H-12), 3.71 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.12 (3H, s), 1.06 (3H, s), 1.04 (3H, s), 0.96 (3H, s), 0.95 (3H, s), 8.12 (2H, m, H-3′, H-7′), 7.45 (2H, m, H-4′, H-6′), 7.61 (1H, m, H-5′), 7.97 (2H, m, H-3″, H-7″), 7.39 (2H, m, H-4″, H-6″), 7.53 (1H, m, H-5″); 13C NMR (125 MHz, CDCl3) δ 34.7 (CH2, C-1), 23.1 (CH2, C-2), 78.9 (CH, C-3), 37.5 (C, C-4), 50.9 (CH, C-5), 17.9 (CH2, C-6), 36.0 (CH2, C-7), 40.8 (C, C-8), 53.0 (CH, C-9), 38.9 (C, C-10), 34.9 (CH2, C-11), 74.1 (CH, C-12), 41.5 (CH, C-13), 49.8 (C, C-14), 31.3 (CH2, C-15), 25.9 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.7 (CH3, C-19), 86.1 (C, C-20), 24.0 (CH3, C-21), 36.3 (CH2, C-22), 26.0 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 25.0 (CH3, C-27), 28.7 (CH3, C-28), 22.0 (CH3, C-29), 16.5 (CH3, C-30), 166.1 (CO, C-1′), 130.8 (C, C-2′), 129.7 (CH, C-3′, C-7′), 128.5 (CH, C-4′, C-6′), 132.8 (CH, C-5′), 165.7 (CO, C-1″), 130.7 (C, C-2″), 129.6 (CH, C-3″, C-7″), 128.4 (CH, C-4″, C-6″), 132.8 (CH, C-5″); HRMS (ESI+) m/z calcd for C44H60O6Na 707.4282, found 707.4279 (M + Na+).

(20S,24R)-epoxy-3β,12β-dinicotinoyl-dammarane-25-ol (18)

White powder, 14% yield; 1H NMR (500 MHz, CDCl3) δ 4.88 (1H, m, H-3), 5.50 (1H, td, J = 10.8, 5.3 Hz, H-12), 3.72 (1H, t, J = 7.4 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.13 (3H, s), 1.11 (3H, s), 1.06 (6H, s), 0.97 (3H, s), 0.95 (3H, s), 9.33 (1H, m, H-3’), 8.82 (1H, m, H-4′), 7.48 (1H, dd, J = 7.9, 4.8 Hz, H-5′), 8.36 (1H, dt, J = 7.9, 1.9 Hz, H-6′), 9.15 (1H, m, H-3″), 8.72 (1H, m, H-4″), 7.34 (1H, dd, J = 8.0, 4.8 Hz, H-5″), 8.23 (1H, dt, J = 8.0, 1.9 Hz, H-6″); 13C NMR (125 MHz, CDCl3) δ 34.6 (CH2, C-1), 25.0 (CH2, C-2), 79.3 (CH, C-3), 37.5 (C, C-4), 50.9 (CH, C-5), 17.9 (CH2, C-6), 35.8 (CH2, C-7), 40.7 (C, C-8), 53.0 (CH, C-9), 39.0 (C, C-10), 34.8 (CH2, C-11), 74.8 (CH, C-12), 41.6 (CH, C-13), 49.8 (C, C-14), 31.3 (CH2, C-15), 25.8 (CH2, C-16), 48.8 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.2 (CH3, C-21), 36.3 (CH2, C-22), 26.1 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.2 (CH3, C-27), 28.7 (CH3, C-28), 21.9 (CH3, C-29), 16.7 (CH3, C-30), 164.7 (CO, C-1′), 127.0 (C, C-2′), 151.0 (CH, C-3′), 153.3 (CH, C-4′), 123.6 (CH, C-5′), 137.4 (CH, C-6′), 164.5 (CO, C-1″), 126.6 (C, C-2″), 150.8 (CH, C-3″), 153.3 (CH, C-4″), 123.4 (CH, C-5″), 137.1 (CH, C-6″); HRMS (ESI+) m/z calcd for C42H59N2O6 687.4368, found 687.4406 (M + H+).

(20S,24R)-epoxy-3β,12β-difuroyl-dammarane-25-ol (19)

White powder, 6% yield; 1H NMR (500 MHz, CDCl3) δ 4.78 (1H, m, H-3), 5.39 (1H, td, J = 10.9, 5.3 Hz, H-12), 3.72 (1H, t, J = 7.5 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.08 (3H, s), 1.03 (3H, s), 1.02 (3H, s), 0.94 (3H, s), 0.93 (3H, s), 7.20 (1H, dd, J = 3.4, 0.9 Hz, H-3′), 6.56 (1H, dd, J = 3.4, 1.8 Hz, H-4′), 7.63 (1H, dd, J = 1.7, 0.9 Hz, H-5′), 7.05 (1H, dd, J = 3.5, 0.9 Hz, H-3″), 6.46 (1H, dd, J = 3.5, 1.7 Hz, H-4″), 7.53 (1H, dd, J = 1.7, 0.8 Hz, H-5″); 13C NMR (125 MHz, CDCl3) δ 34.6 (CH2, C-1), 23.8 (CH2, C-2), 79.0 (CH, C-3), 37.4 (C, C-4), 50.6 (CH, C-5), 17.9 (CH2, C-6), 35.8 (CH2, C-7), 40.8 (C, C-8), 52.8 (CH, C-9), 38.8 (C, C-10), 35.2 (CH2, C-11), 74.2 (CH, C-12), 41.5 (CH, C-13), 49.8 (C, C-14), 31.2 (CH2, C-15), 29.7 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.7 (CH3, C-19), 86.0 (C, C-20), 23.2 (CH3, C-21), 35.9 (CH2, C-22), 25.9 (CH2, C-23), 83.6 (CH, C-24), 71.3 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.6 (CH3, C-28), 21.9 (CH3, C-29), 16.6 (CH3, C-30), 158.6 (CO, C-1′), 145.3 (C, C-2′), 118.0 (CH, C-3′), 111.9 (CH, C-4′), 146.4 (CH, C-5′), 158.0 (CO, C-1″), 145.2 (C, C-2″), 117.3 (CH, C-3″), 111.8 (CH, C-4″), 146.2 (CH, C-5″); HRMS (ESI+) m/z calcd for C40H56O8Na 687.3867, found 687.3847 (M + Na+).

(20S,24R)-epoxy-3β,12β-dithenoyl-dammarane-25-ol (20)

White powder, 6% yield; 1H NMR (500 MHz, CDCl3) δ 4.77 (1H, m, H-3), 5.37 (1H, td, J = 10.8, 5.3 Hz, H-12), 3.72 (1H, t, J = 7.4 Hz, H-24), 1.22 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.09 (3H, s), 1.05 (3H, s), 1.03 (3H, s), 0.94 (3H, s), 0.94 (3H, s), 7.85 (1H, dd, J = 3.7, 1.3 Hz, H-3′), 7.17 (1H, dd, J = 5.0, 3.7 Hz, H-4′), 7.60 (1H, dd, J = 5.0, 1.2 Hz, H-5′), 7.70 (1H, dd, J = 3.7, 1.3 Hz, H-3″), 7.05 (1H, m, H-4′), 7.50 (1H, dd, J = 5.0, 1.2 Hz, H-5″); 13C NMR (125 MHz, CDCl3) δ 34.6 (CH2, C-1), 23.9 (CH2, C-2), 79.2 (CH, C-3), 37.5 (C, C-4), 50.6 (CH, C-5), 17.9 (CH2, C-6), 36.0 (CH2, C-7), 40.8 (C, C-8), 52.9 (CH, C-9), 38.8 (C, C-10), 35.0 (CH2, C-11), 74.5 (CH, C-12), 41.5 (CH, C-13), 49.8 (C, C-14), 31.2 (CH2, C-15), 26.0 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.2 (CH3, C-21), 36.3 (CH2, C-22), 25.9 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 24.9 (CH3, C-27), 28.7 (CH3, C-28), 21.8 (CH3, C-29), 16.5 (CH3, C-30), 161.8 (CO, C-1’), 134.9 (C, C-2′), 133.4 (CH, C-3′), 132.5 (CH, C-4′), 127.9 (CH, C-5′), 161.5 (CO, C-1″), 134.8 (C, C-2″), 133.0 (CH, C-3″), 132.1 (CH, C-4″), 127.7 (CH, C-5″); HRMS (ESI+) m/z calcd for C40H56O6S2Na 719.3411, found 719.3389 (M + Na+).

(20S,24R)-epoxy-3β,12β-dicinnamoyl-dammarane-25-ol (21)

Light yellow powder, 8% yield; 1H NMR (500 MHz, CDCl3) δ 4.72 (1H, m, H-3), 5.30 (1H, td, J = 10.7, 5.3 Hz, H-12), 3.72 (1H, t, J = 7.4 Hz, H-24), 1.23 (3H, s), 1.14 (3H, s), 1.13 (3H, s), 1.08 (3H, s), 1.05 (3H, s), 1.03 (3H, s), 0.94 (3H, s), 0.91 (3H, s), 6.57 (1H, d, J = 16.0 Hz, H-2′), 7.70 (1H, d, J = 16.0 Hz, H-3’), 7.59 (2H, m, H-5′, H-9′), 7.38 (3H, m, H-6′, H-7′, H-8′), 7.66 (1H, d, J = 16.0 Hz, H-3″), 7.47 (2H, m, H-5″, H-9″), 7.35-7.34 (3H, m, H-6″, H-7″, H-8″); 13C NMR (125 MHz, CDCl3) δ 34.7 (CH2, C-1), 24.0 (CH2, C-2), 78.3 (CH, C-3), 37.2 (C, C-4), 50.5 (CH, C-5), 17.9 (CH2, C-6), 35.8 (CH2, C-7), 40.7 (C, C-8), 52.8 (CH, C-9), 39.0 (C, C-10), 34.9 (CH2, C-11), 73.5 (CH, C-12), 41.4 (CH, C-13), 49.8 (C, C-14), 31.2 (CH2, C-15), 26.0 (CH2, C-16), 49.0 (CH, C-17), 16.8 (CH3, C-18), 16.8 (CH3, C-19), 86.1 (C, C-20), 23.1 (CH3, C-21), 35.8 (CH2, C-22), 25.9 (CH2, C-23), 83.6 (CH, C-24), 71.2 (C, C-25), 27.4 (CH3, C-26), 25.0 (CH3, C-27), 28.5 (CH3, C-28), 21.9 (CH3, C-29), 16.5 (CH3, C-30), 166.7 (CO, C-1′), 119.0 (CH, C-2′), 144.9 (CH, C-3′), 134.8 (C, C-4′), 128.1 (CH, C-5′, C-9′), 128.9 (CH, C-6′, C-8′), 130.3 (CH, C-7′), 166.2 (CO, C-1″), 118.8 (CH, C-2″), 144.4 (CH, C-3″), 134.6 (C, C-4″), 128.0 (CH, C-5″, C-9″), 128.9 (CH, C-6″, C-8″), 130.2 (CH, C-7″); HRMS (ESI+) m/z calcd for C48H64O6Na 759.4595, found 759.4600 (M + Na+).

General procedure for the synthesis of compounds 8 and 15

To a solution of (20 S,24 R)-epoxy-dammarane-3β,12β,25-triol (23.8 mg, 0.05 mmol) in pyridine (0.6 mL) was added phthalic anhydride (13.3 mg, 0.09 mmol) at room temperature. The solution was then heated to 80 °C and stirred for 24 h. Then, the reaction mixture was diluted with EtOAc and washed with 5% HCl aqueous solution. The aqueous layer was extracted with EtOAc and the combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (chloroform-methanol-acetic acid, 98:2:0.01) to give compounds 8 and 15.

(20S,24R)-epoxy-3β-(2-carboxybenzoyl)-dammarane-12β,25-diol (8)

White powder, 10% yield; 1H NMR (600 MHz, CDCl3) δ 4.93 (1H, m, H-3), 3.99 (1H, m, H-12), 3.72 (1H, t, J = 7.1 Hz, H-24), 1.25 (3H, s), 1.17 (3H, s), 1.12 (3H, s), 1.11 (3H, s), 1.06 (6H, s), 0.95 (3H, s), 0.91 (6H, s), 0.84 (3H, s), 7.83 (1H, m, H-4′), 7.83 (1H, m, H-7′), 7.55 (2H, m, H-5′, H-6′); 13C NMR(150 MHz, CDCl3) δ 31.9 (CH2, C-1), 22.3 (CH2, C-2), 80.3 (CH, C-3), 37.2 (C, C-4), 49.9 (CH, C-5), 16.6 (CH2, C-6), 35.7 (CH2, C-7), 41.2 (C, C-8), 54.9 (CH, C-9), 38.9 (C, C-10), 39.3 (CH2, C-11), 71.4 (CH, C-12), 41.0 (CH, C-13), 50.4 (C, C-14), 31.0 (CH2, C-15), 25.8 (CH2, C-16), 49.2 (CH, C-17), 16.5 (CH3, C-18), 17.8 (CH3, C-19), 86.1 (C, C-20), 23.9 (CH3, C-21), 36.2 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.6 (C, C-25), 27.3 (CH3, C-26), 24.3 (CH3, C-27), 28.3 (CH3, C-28), 21.9 (CH3, C-29), 16.5 (CH3, C-30), 168.2 (C, C-1′, C-8′), 133.2 (C, C-2′, C-3′), 129.5 (C, C-4′), 130.7 (C, C-5′), 131.1 (C, C-6′), 129.1 (C, C-7′); HRMS (ESI) m/z calcd for C38H55O7 623.3953, found 623.3935 (M-H).

(20S,24R)-epoxy-12β-(2-carboxybenzoyl)-dammarane-3β,25-diol (15)

White powder, 28% yield; 1H NMR (500 MHz, CDCl3) δ 3.36 (1H, m, H-3), 5.48 (1H, td, J = 10.8, 5.7 Hz, H-12), 3.80 (1H, t, J = 7.0 Hz, H-24), 1.21 (3H, s), 1.18 (3H, s), 1.15 (3H, s), 1.06 (6H, s), 0.98 (3H, s), 0.95 (3H, s), 0.85 (3H, s), 7.84 (1H, m, H-4’), 7.52 (3H, m, H-5′-H-7′); 13C NMR (125 MHz, CDCl3) δ 34.2 (CH2, C-1), 25.3 (CH2, C-2), 75.8 (CH, C-3), 37.9 (C, C-4), 48.5 (CH, C-5), 18.0 (CH2, C-6), 35.0 (CH2, C-7), 41.5 (C, C-8), 52.7 (CH, C-9), 38.9 (C, C-10), 32.9 (CH2, C-11), 75.1 (C, C-12), 40.4 (CH, C-13), 49.9 (C, C-14), 31.1 (CH2, C-15), 26.1 (CH2, C-16), 48.9 (CH, C-17), 16.9 (CH3, C-18), 16.7 (CH3, C-19), 86.7 (C, C-20), 23.6 (CH3, C-21), 35.8 (CH2, C-22), 26.6 (CH2, C-23), 83.5 (CH, C-24), 72.4 (C, C-25), 27.3 (CH3, C-26), 24.7 (CH3, C-27), 28.8 (CH3, C-28), 22.2 (CH3, C-29), 16.4 (CH3, C-30), 167.5 (C, C-1′, C-8′), 133.7 (C, C-2′, C-3′), 129.8 (C, C-4′), 130.5 (C, C-5′), 131.3 (C, C-6′), 127.9 (C, C-7′); HRMS (ESI) m/z calcd for C38H55O7 623.3953, found 623.3922 (M-H).

(20S,24R)-epoxy-12β,25-dihydroxy-dammarane-3-one (22)

The (20 S,24 R)-epoxy-dammarane-3β,12β,25-triol (100.0 mg, 0.21 mmol) was dissolved in toluene (3.0 mL) followed by the addition of aluminium isopropoxide (107.2 mg, 0.53 mmol). After stirred at room temperature for 1 h, acetone was added and the reaction was heated to reflux for 7 h. The reaction was cooled to room temperature and quenched by the addition of 5% HCl aqueous solution. The layers were separated and the aqueous phase was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to remove EtOAc. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 25:75, 35:65) to give compound 22 (70% yield) as a white powder, 1H NMR (400 MHz, CDCl3) δ 3.92 (1H, m, H-12), 3.73 (1H, t, J = 7.4 Hz, H-24), 1.25 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 1.11 (3H, s), 1.06 (3H, s), 1.04 (3H, s), 1.00 (3H, s), 0.89 (3H, s); 13C NMR (100 MHz, CDCl3) δ 42.0 (CH2, C-1), 20.7 (CH2, C-2), 218.8 (CO, C-3), 38.2 (C, C-4), 54.8 (CH, C-5), 19.6 (CH2, C-6), 35.1 (CH2, C-7), 40.6 (C, C-8), 55.2 (CH, C-9), 47.7 (C, C-10), 39.5 (CH2, C-11), 71.2 (CH, C-12), 41.6 (CH, C-13), 49.8 (C, C-14), 31.0 (CH2, C-15), 25.7 (CH2, C-16), 49.2 (CH, C-17), 16.7 (CH3, C-18), 16.4 (CH3, C-19), 85.9 (C, C-20), 23.3 (CH3, C-21), 36.3 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.5 (CH3, C-26), 24.3 (CH3, C-27), 29.7 (CH3, C-28), 22.7 (CH3, C-29), 16.2 (CH3, C-30); HRMS (ESI) m/z calcd for C31H51O6 519.3691, found 519.3693 (M + HCOO).

General procedure for the synthesis of compounds 23 and 24

To a solution of (20 S,24 R)-epoxy-dammarane-3β,12β,25-triol (30.0 mg, 0.06 mmol) in dry CH2Cl2 (2 mL) was added pyridinium chlorochromate (PCC, 25.8 mg, 0.12 mmol) and the mixture was stirred at room temperature for 24 h. The suspension was then filtered by a Celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 35:65) to afford compounds 23 and 24.

(20S,24R)-epoxy-12-oxo-dammarane-3β,25-diol (23)

White powder, 20% yield; 1H NMR (600 MHz, CDCl3) δ 3.37 (1H, m, H-3), 3.70 (1H, t, J = 7.4 Hz, H-24), 1.23 (3H, s), 1.18 (3H, s), 1.13 (3H, s), 1.09 (3H, s), 1.09 (3H, s), 0.95 (3H, s), 0.91 (3H, s), 0.83 (3H, s); 13C NMR (150 MHz, CDCl3) δ 32.6 (CH2, C-1), 25.3 (CH2, C-2), 76.2 (CH, C-3), 36.8 (C, C-4), 49.5 (CH, C-5), 18.0 (CH2, C-6), 34.5 (CH2, C-7), 43.5 (C, C-8), 44.3 (CH, C-9), 37.6 (C, C-10), 46.9 (CH2, C-11), 212.2 (CO, C-12), 63.5 (CH, C-13), 50.0 (C, C-14), 30.5 (CH2, C-15), 26.0 (CH2, C-16), 48.9 (CH, C-17), 17.9 (CH3, C-18), 16.8 (CH3, C-19), 85.9 (C, C-20), 23.4 (CH3, C-21), 36.1 (CH2, C-22), 26.3 (CH2, C-23), 83.7 (CH, C-24), 71.6 (C, C-25), 27.6 (CH3, C-26), 24.8 (CH3, C-27), 28.6 (CH3, C-28), 22.4 (CH3, C-29), 16.6 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H50O4Na 497.3601, found 497.3573 (M + Na+).

(20S,24R)-epoxy-3,12-dioxo-dammarane-25-ol (24)

White powder, 30% yield; 1H NMR (500 MHz, CDCl3) δ 3.71 (1H, t, J = 7.4 Hz, H-24), 1.33 (3H, s), 1.18 (3H, s), 1.14 (3H, s), 1.11 (6H, s), 1.06 (3H, s), 1.04 (3H, s), 0.99 (3H, s); 13C NMR (125 MHz, CDCl3) δ 38.8 (CH2, C-1), 33.8 (CH2, C-2), 217.0 (CO, C-3), 36.3 (C, C-4), 55.7 (CH, C-5), 19.2 (CH2, C-6), 34.1 (CH2, C-7), 43.0 (C, C-8), 44.0 (CH, C-9), 47.7 (C, C-10), 46.5 (CH2, C-11), 211.4 (CO, C-12), 62.8 (CH, C-13), 49.7 (C, C-14), 30.4 (CH2, C-15), 25.8 (CH2, C-16), 49.3 (CH, C-17), 17.5 (CH3, C-18), 16.4 (CH3, C-19), 85.6 (C, C-20), 23.3 (CH3, C-21), 35.8 (CH2, C-22), 26.1 (CH2, C-23), 83.5 (CH, C-24), 71.4 (C, C-25), 26.2 (CH3, C-26), 24.6 (CH3, C-27), 27.3 (CH3, C-28), 21.5 (CH3, C-29), 15.7 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H48O4Na 495.3445, found 495.3416 (M + Na+).

(20S,24R)-epoxy-3-oxime-dammarane-12β,25-diol (25)

To a stirred solution of compound 22 (30.0 mg, 0.06 mmol) in 2.2 mL of ethanol-water (10:1, v/v) was added hydroxylamine hydrochloride (NH2OH•HCl, 11.0 mg, 0.16 mmol) and sodium acetate trihydrate (CH3COONa•3H2O, 21.6 mg, 0.16 mmol) in sequence. The reaction mixture was refluxed for 3 h. After cooling to room temperature, the organic solvent was removed under reduced pressure. The residue was taken up in EtOAc (5.0 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was subjected to flash column chromatography on silica gel (acetone-petroleum ether, 15:85, 25:75) to provide compound 25 (91% yield) as a white solid, 1H NMR (400 MHz, CDCl3) δ 3.93 (1H, td, J = 10.6, 4.9 Hz, H-12), 3.73 (1H, t, J = 7.2 Hz, H-24), 1.20 (3H, s), 1.15 (3H, s), 1.14 (3H, s), 1.13 (3H, s), 1.10 (6H, br s), 0.99 (3H, s), 0.90 (3H, s); 13C NMR (100 MHz, CDCl3) δ 41.1 (CH2, C-1), 19.0 (CH2, C-2), 167.2 (C, C-3), 38.7 (C, C-4), 55.2 (CH, C-5), 17.5 (CH2, C-6), 35.5 (CH2, C-7), 40.7 (C, C-8), 55.4 (CH, C-9), 40.6 (C, C-10), 39.4 (CH2, C-11), 71.2 (CH, C-12), 41.6 (CH, C-13), 49.8 (C, C-14), 30.9 (CH2, C-15), 25.6 (CH2, C-16), 49.2 (CH, C-17), 16.7 (CH3, C-18), 16.4 (CH3, C-19), 85.9 (C, C-20), 23.3 (CH3, C-21), 36.3 (CH2, C-22), 26.3 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.2 (CH3, C-28), 22.6 (CH3, C-29), 16.2 (CH3, C-30); HRMS (ESI) m/z calcd for C31H52NO6 534.3800, found 534.3794 (M + HCOO).

(20S,24R)-epoxy-3β-(2-carboxybenzoyl)-12-oxo-dammarane-25-ol (26)

To a solution of compound 23 (12.0 mg, 0.03 mmol) in pyridine (0.6 mL) was added o-phthalic anhydride (22.2 mg, 0.15 mmol) and the mixture was refluxed for 72 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc, and washed with 5% HCl aqueous solution. The aqueous phase was extracted with EtOAc, the combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether-acetic acid, 20:80:0.1, 25:75:0.1) to give compound 26 (76% yield) as a white solid, 1H NMR (400 MHz, CDCl3) δ 4.92 (1H, m, H-3), 3.70 (1H, t, J = 7.4 Hz, H-24), 1.23 (3H, s), 1.20 (3H, s), 1.19 (3H, s), 1.13 (3H, s), 1.10 (3H, s), 1.08 (3H, s), 0.94 (3H, s), 0.89 (3H, s), 7.90 (1H, m, H-4’), 7.59 (3H, m, H-5′-H-7′); 13C NMR (100 MHz, CDCl3) δ 33.3 (CH2, C-1), 22.2 (CH2, C-2), 80.1 (CH, C-3), 36.5 (C, C-4), 50.0 (CH, C-5), 17.7 (CH2, C-6), 34.2 (CH2, C-7), 43.3 (C, C-8), 44.1 (CH, C-9), 36.9 (C, C-10), 46.6 (CH2, C-11), 212.1 (C, C-12), 63.1 (CH, C-13), 49.8 (C, C-14), 30.3 (CH2, C-15), 25.8 (CH2, C-16), 49.3 (CH, C-17), 17.7 (CH3, C-18), 16.7 (CH3, C-19), 85.7 (C, C-20), 23.2 (CH3, C-21), 35.9 (CH2, C-22), 26.1 (CH2, C-23), 83.4 (CH, C-24), 71.5 (C, C-25), 27.3 (CH3, C-26), 24.5 (CH3, C-27), 28.0 (CH3, C-28), 21.9 (CH3, C-29), 16.4 (CH3, C-30), 167.9 (C, C-1′, C-8′), 134.1 (C, C-2′, C-3′), 130.0 (C, C-4′), 130.6 (C, C-5′), 131.9 (C, C-6′), 128.5 (C, C-7′); HRMS (ESI) m/z calcd for C38H53O7 621.3797, found 621.3787 (M-H).

(20S,24R)-epoxy-2-hydroxymethlidene-3-oxo-dammarane12β,25-diol (27)

To a round-bottom bottle equipped with Na (0.5 g) was added ethyl ether (5.0 mL), and the mixture was refluxed for 1 h. After cooling to 0 °C, a solution of compound 22 (20.0 mg, 0.04 mmol) in ethyl formate (1.0 mL) was added dropwise to the mixture. After 30 min, the solution was allowed to warm to room temperature and stirred for 6 h before it was quenched by the addition of EtOH (2.0 mL). The mixture was poured into 5 mL water. The aqueous layer was extracted with EtOAc and the combined organic extracts were dried over anhydrous MgSO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 6:94) to give compound 27 (76% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 3.39 (2H, d, J = 14.9 Hz, H-1), 4.00 (1H, td, J = 10.7, 4.9 Hz, H-12), 3.74 (1H, t, J = 7.2 Hz, H-24), 1.22 (3H, s), 1.21 (3H, s), 1.15 (3H, s), 1.13 (6H, overlap), 1.03 (6H, overlap), 0.93 (3H, s), 8.60 (1H, s, H-1′); 13C NMR (100 MHz, CDCl3) δ 41.7 (CH2, C-1), 106.5 (C, C-2), 189.0 (C, C-3), 40.4 (C, C-4), 53.4 (CH, C-5), 19.3 (CH2, C-6), 35.0 (CH2, C-7), 40.5 (C, C-8), 53.1 (CH, C-9), 37.4 (C, C-10), 39.7 (CH2, C-11), 71.3 (CH, C-12), 41.5 (CH, C-13), 49.8 (C, C-14), 31.0 (CH2, C-15), 25.7 (CH2, C-16), 49.1 (CH, C-17), 16.2 (CH3, C-18), 15.2 (CH3, C-19), 85.9 (C, C-20), 23.5 (CH3, C-21), 36.1 (CH2, C-22), 26.2 (CH2, C-23), 83.3 (CH, C-24), 71.5 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.4 (CH3, C-28), 20.6 (CH3, C-29), 16.3 (CH3, C-30), 189.8 (CH, C-1’); HRMS (ESI) m/z calcd for C31H49O5 501.3585, found 501.3592 (M-H).

(20S,24R)-epoxy-2- hydroxymethyl-3-oxo-dammarane12β,25 -diol (28)

To a solution of compound 27 (20.0 mg, 0.04 mmol) in methanol (1.0 mL) was added NaBH4 (3.0 mg, 0.08 mmol). The reaction mixture was allowed to stir at room temperature for 6 h before it was quenched by the addition of water (1.0 mL). The aqueous phase was extracted with EtOAc, the combined organic phase was dried over anhydrous MgSO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 15:85, 20:80) to give compound 28 (69% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 2.90 (1H, m, H-2), 3.86 (1H, td, J = 10.9, 4.7 Hz, H-12), 3.73 (1H, t, J = 7.3 Hz, H-24), 1.21 (3H, s), 1.14 (3H, s), 1.12 (6H, s), 1.08 (3H, s), 0.97 (3H, s), 0.94 (3H, s), 0.86 (3H, s), 2.83 (1H, m, H-1′), 3.53 (1H, m, H-1′); 13C NMR (100 MHz, CDCl3) δ 46.5 (CH2, C-1), 43.5 (CH, C-2), 222.8 (C, C-3), 40.4 (C, C-4), 53.1 (CH, C-5), 19.8 (CH2, C-6), 34.6 (CH2, C-7), 41.2 (C, C-8), 54.7 (CH, C-9), 37.7 (C, C-10), 39.2 (CH2, C-11), 71.1 (CH, C-12), 41.6 (CH, C-13), 49.7 (C, C-14), 30.9 (CH2, C-15), 25.6 (CH2, C-16), 49.0 (CH, C-17), 18.3 (CH3, C-18), 15.7 (CH3, C-19), 85.9 (C, C-20), 23.4 (CH3, C-21), 36.2 (CH2, C-22), 26.3 (CH2, C-23), 83.3 (CH, C-24), 71.4 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 29.4 (CH3, C-28), 19.4 (CH3, C-29), 16.1 (CH3, C-30), 63.0 (CH2, C-1′); HRMS (ESI+) m/z calcd for C31H52O5Na 527.3707, found 527.3694 (M + Na+).

(20S,24R)-epoxy-[2,3-d]-isoxazole-dammarane-12β,25-diol (29)

To a solution of compound 27 (9.0 mg, 0.02 mmol) in 2.2 mL ethanol-water (10:1, v/v) was added hydroxylamine hydrochloride (NH2OH•HCl, 3.1 mg, 0.05 mmol). The reaction mixture was refluxed for 3 h. After cooling to room temperature, the solution was diluted with EtOAc, the organic phase was separated and washed by brine. The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 5:95) to give compound 29 (56% yield) as a white solid, 1H NMR (400 MHz, CDCl3) δ 3.43 (1H, dd, J = 15.9, 5.4 Hz, H-1), 4.02 (1H, td, J = 10.7, 5.0 Hz, H-12), 3.74 (1H, t, J = 7.2 Hz, H-24), 1.32 (3H, s), 1.24 (3H, s), 1.22 (3H, s), 1.16 (3H, s), 1.13 (3H, s), 1.03 (3H, s), 1.01 (3H, s), 0.94 (3H, s), 7.96 (1H, s, H-1′); 13C NMR (100 MHz, CDCl3) δ 37.9 (CH2, C-1), 109.7 (C, C-2), 172.2 (C, C-3), 49.8 (C, C-4), 53.8 (CH, C-5), 18.5 (CH2, C-6), 35.1 (CH2, C-7), 40.7 (C, C-8), 54.2 (CH, C-9), 35.1 (C, C-10), 39.8 (CH2, C-11), 71.2 (CH, C-12), 41.5 (CH, C-13), 49.8 (C, C-14), 31.0 (CH2, C-15), 25.7 (CH2, C-16), 49.1 (CH, C-17), 16.2 (CH3, C-18), 16.2 (CH3, C-19), 85.9 (C, C-20), 23.6 (CH3, C-21), 36.1 (CH2, C-22), 26.2 (CH2, C-23), 83.3 (CH, C-24), 71.5 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 29.0 (CH3, C-28), 21.3 (CH3, C-29), 16.3 (CH3, C-30), 150.6 (CH, C-1′); HRMS (ESI+) m/z calcd for C31H50NO4 500.3734, found 500.3702 (M + H+).

(20S,24R)-epoxy-3,4-lactone-dammarane-12β,25-diol (30)

To a solution of compound 22 (15.0 mg, 0.03 mmol) in 1.5 mL of DCM was added NaHCO3 (10.8 mg, 0.12 mmol) and m-CPBA (10.4 mg, 0.06 mmol). The resulting suspension was stirred for 12 h at room temperature before it was quenched with sat. aq. Na2S2O3 aqueous solution. Layers were separated, and the aqueous layer was extracted with DCM, and the combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 10:90) to give compound 30 (71% yield) as a white solid, 1H NMR (400 MHz, CDCl3) δ 3.90 (1H, m, H-12), 3.73 (1H, t, J = 7.3 Hz, H-24), 1.51 (3H, s), 1.43 (3H, s), 1.30 (3H, s), 1.21 (3H, s), 1.15 (3H, s), 1.13 (3H, s), 1.03 (3H, s), 0.90 (3H, s); 13C NMR (100 MHz, CDCl3) δ 44.1 (CH2, C-1), 33.1 (CH2, C-2), 175.4 (C, C-3), 85.6 (C, C-4), 51.8 (CH, C-5), 23.8 (CH2, C-6), 34.7 (CH2, C-7), 40.2 (C, C-8), 56.2 (CH, C-9), 39.8 (C, C-10), 39.3 (CH2, C-11), 71.0 (CH, C-12), 41.9 (CH, C-13), 49.6 (C, C-14), 30.7 (CH2, C-15), 25.6 (CH2, C-16), 48.9 (CH, C-17), 15.9 (CH3, C-18), 19.3 (CH3, C-19), 85.8 (C, C-20), 23.3 (CH3, C-21), 36.4 (CH2, C-22), 26.3 (CH2, C-23), 83.3 (CH, C-24), 71.4 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 29.6 (CH3, C-28), 27.8 (CH3, C-29), 15.7 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H50O5Na 513.3550, found 513.3516 (M + Na+).

(20S,24R)-epoxy-3-carboxyl-dammarane-4,12β,25-triol (31)

To a solution of compound 30 (24.0 mg, 0.05 mmol) in 3 mL of methanol was added 10% NaOH aqueous solution (1 mL) and the mixture was heated to reflux for 5 h. After the completion of hydrolysis, the solution was neutralized with 1 M HCl and the mixture was extracted with EtOAc. Combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (chloroform-methanol, 10:90) to give compound 31 (82% yield) as a white solid, 1H NMR (400 MHz, CD3OD) δ 2.69 (1H, m, H-2), 3.81 (1H, td, J = 10.9, 4.7 Hz, H-12), 3.72 (1H, t, J = 7.2 Hz, H-24), 1.27 (6H, s), 1.24 (3H, s), 1.13 (3H, s), 1.12 (6H, s), 1.01 (3H, s), 0.91 (3H, s); 13C NMR (100 MHz, CD3OD) δ 35.1 (CH2, C-1), 30.0 (CH2, C-2), 75.2 (C, C-4), 49.2 (CH, C-5), 21.9 (CH2, C-6), 35.4 (CH2, C-7), 41.8 (C, C-8), 51.6 (CH, C-9), 40.0 (C, C-10), 38.6 (CH2, C-11), 70.8 (CH, C-12), 41.6 (CH, C-13), 49.8 (C, C-14), 30.6 (CH2, C-15), 25.0 (CH2, C-16), 49.2 (CH, C-17), 15.4 (CH3, C-18), 19.6 (CH3, C-19), 86.0 (C, C-20), 24.1 (CH3, C-21), 36.0 (CH2, C-22), 26.0 (CH2, C-23), 83.4 (CH, C-24), 71.4 (C, C-25), 27.2 (CH3, C-26), 24.9 (CH3, C-27), 31.9 (CH3, C-28), 22.0 (CH3, C-29), 14.9 (CH3, C-30); HRMS (ESI) m/z calcd for C30H51O6 507.3691, found 507.3673 (M-H).

(20S,24R)-epoxy-dammarane-3,4,12β,25-tetrol (32)

Under a nitrogen atmosphere, a solution of compound 30 (19.0 mg, 0.04 mmol) in THF was treated dropwise with solution of LiAlH4 (5.2 mg, 0.12 mmol) in 1.5 mL of dried THF at 0 °C. After complete addition, the solution was heated to 50 °C and stirred at the same temperature for 12 h. After cooling to 0 °C, water and 0.1 M NaOH aqueous solution was added slowly and filtered. The filtrate was extracted with EtOAc, and the combine organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 20:80) to give compound 32 (50% yield) as a white solid, 1H NMR (400 MHz, CDCl3) δ 2.92 (1H, m, H-3), 3.80 (1H, td, J = 10.7, 4.6 Hz, H-12), 3.72 (1H, t, J = 7.2 Hz, H-24), 1.32 (3H, s), 1.30 (3H, s), 1.25 (3H, s), 1.23 (3H, s), 1.21 (3H, s), 1.14 (3H, s), 1.12 (3H, s), 0.99 (3H, s); 13C NMR (100 MHz, CDCl3) δ 35.3 (CH2, C-1), 27.3 (CH2, C-2), 63.3 (CH2, C-3), 76.6 (C, C-4), 46.0 (CH, C-5), 22.5 (CH2, C-6), 35.9 (CH2, C-7), 42.4 (C, C-8), 51.4 (CH, C-9), 40.2 (C, C-10), 39.8 (CH2, C-11), 71.7 (CH, C-12), 41.6 (CH, C-13), 50.0 (C, C-14), 31.0 (CH2, C-15), 25.6 (CH2, C-16), 49.1 (CH, C-17), 16.0 (CH3, C-18), 20.8 (CH3, C-19), 86.0 (C, C-20), 23.5 (CH3, C-21), 37.8 (CH2, C-22), 26.3 (CH2, C-23), 83.3 (CH, C-24), 71.6 (C, C-25), 27.4 (CH3, C-26), 24.3 (CH3, C-27), 28.2 (CH3, C-28), 22.0 (CH3, C-29), 16.3 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H54O5Na 517.3863, found 517.3848 (M + Na+).

Procedure for the synthesis of compounds 33 and 34

To a solution of compound 16 (30.0 mg, 0.05 mmol) in dry CH2Cl2 (1.0 mL) was added pyridinium chlorochromate (PCC, 46.6 mg, 0.22 mmol) at room temperature. The resultant mixture was then heated to 40 °C and stirred at the same temperature for 12 h. Upon consumption of starting material, the suspension was filtered by a Celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 5:95 to 10:90) to afford intermediate. To a solution of intermediate (24.0 mg, 0.05 mmol) in MeOH (3.0 mL) was added 10% NaOH aqueous solution (1.0 mL) at room temperature. Then, the mixture was heated to reflux and stirred overnight. After cooling to room temperature, the organic solvent was removed under reduced pressure. Then the crude was diluted with EtOAc, washed with 5% HCl aqueous solution, sat. aq. NaHCO3, and brine in sequence, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (acetone-petroleum ether, 25:75, 10:90) to give compound 33 (91% yield) as a white powder.

Under a nitrogen atmosphere, a solution of compound 33 (5.3 mg, 0.14 mmol) in THF was treated dropwise with a solution of LiAlH4 (5.2 mg, 0.12 mmol) in 1.5 mL of dried THF at 0 °C. After complete addition, the solution was heated to 50 °C and stirred at the same temperature for 12 h. After cooling to 0 °C, water and 0.1 M NaOH aqueous solution was added slowly and filtered. The filtrate was extracted with EtOAc, and the combine organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 20:80 to 35:65) to give compound 34 (35% yield) as a white solid.

20S-epoxy-3β,12β-dihydroxy-dammarane -24-one (33)

White powder, 91% yield; 1H NMR (400 MHz, CD3OD) δ 3.30 (1H, m, H-3), 3.90 (1H, td, J = 10.5, 5.5 Hz, H-12), 1.37 (3H, s), 1.06 (3H, s), 1.00 (6H, s), 0.98 (3H, s), 0.92 (3H, s), 0.86 (3H, s); 13C NMR (100 MHz, CD3OD) δ 36.3 (CH2, C-1), 26.2 (CH, C-2), 76.8 (CH, C-3), 38.9 (C, C-4), 50.5 (CH, C-5), 19.1 (CH2, C-6), 37.1 (CH2, C-7), 42.1 (C, C-8), 56.1 (CH, C-9), 40.3 (C, C-10), 39.6 (CH2, C-11), 71.4 (CH, C-12), 42.9 (CH, C-13), 51.2 (C, C-14), 31.8 (CH2, C-15), 26.5 (CH2, C-16), 50.6 (CH, C-17), 17.2 (CH3, C-18), 17.1 (CH3, C-19), 91.9 (C, C-20), 25.5 (CH3, C-21), 31.8 (CH2, C-22), 30.0 (CH2, C-23), 179.6 (CO, C-24), 29.6 (CH3, C-28), 23.0 (CH3, C-29), 16.5 (CH3, C-30); HRMS (ESI) m/z calcd for C28H45O6 477.3222, found 477.3203 (M + HCOO).

20S-protopanaxadiol-24-ol (34)

White powder, 35% yield; 1H NMR (400 MHz, CD3OD) δ 3.53 (1H, m, H-3), 3.91 (1H, td, J = 11.0, 5.5 Hz, H-12), 3.73 (1H, t, J = 7.3 Hz, H-24), 1.13 (3H, s), 1.06 (3H, s), 0.99 (3H, s), 0.96 (3H, s), 0.92 (3H, s), 0.86 (3H, s); 13C NMR (100 MHz, CD3OD) δ 35.0 (CH2, C-1), 24.5 (CH, C-2), 74.5 (CH, C-3), 37.5 (C, C-4), 49.2 (CH, C-5), 17.8 (CH2, C-6), 35.7 (CH2, C-7), 40.5 (C, C-8), 54.8 (CH, C-9), 38.9 (C, C-10), 39.1 (CH2, C-11), 70.3 (CH, C-12), 40.7 (CH, C-13), 50.0 (C, C-14), 30.4 (CH2, C-15), 25.6 (CH2, C-16), 49.4 (CH, C-17), 15.8 (CH3, C-18), 15.7 (CH3, C-19), 74.2 (C, C-20), 23.9 (CH3, C-21), 37.1 (CH2, C-22), 26.4 (CH2, C-23), 62.3 (CH2, C-24), 28.2 (CH3, C-28), 23.9 (CH3, C-29), 15.4 (CH3, C-30); HRMS (ESI) m/z calcd for C28H49O6 481.3535, found 481.3530 (M + HCOO).

20S-24,25-dihydro-protopanaxadiol (36)

A suspension of 10% Pd/C (2.4 mg) and 20(S)-PPD (21.0 mg, 0.05 mmol) in ethanol (1.0 mL) was stirred at room temperature under hydrogen atmosphere. After being stirred for 12 h, the suspension was filtered through a Celite pad and the pad was washed with CH2Cl2. The filtrate was concentrated and purified by column chromatography on silica gel (acetone- petroleum ether, 10:90) to give compound 36 (80% yield) as a white powder, 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.2, 5.0 Hz, H-3), 3.59 (1H, td, J = 10.3, 5.2 Hz, H-12), 1.18 (3H, s), 0.99 (3H, s), 0.98 (3H, s), 0.88 (12H, overlap), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 38.9 (CH2, C-1), 27.4 (CH2, C-2), 78.9 (CH, C-3), 39.0 (C, C-4), 55.8 (CH, C-5), 18.3 (CH2, C-6), 34.8 (CH2, C-7), 39.7 (C, C-8), 50.1 (CH, C-9), 37.1 (C, C-10), 31.0 (CH2, C-11), 70.9 (C, C-12), 47.7 (CH, C-13), 51.6 (C, C-14), 31.2 (CH2, C-15), 26.6 (CH2, C-16), 53.5 (CH, C-17), 16.1 (CH3, C-18), 15.6 (CH3, C-19), 74.3 (C, C-20), 27.1 (CH3, C-21), 35.1 (CH2, C-22), 21.3 (CH2, C-23), 39.8 (CH2, C-24), 28.2 (CH, C-25), 22.7 (CH3, C-26), 22.6 (CH3, C-27), 28.1 (CH3, C-28), 15.4 (CH3, C-29), 16.8 (CH3, C-30); HRMS (ESI) m/z calcd for C31H55O5 507.4055, found 507.4067 (M + HCOO).

20S-3β,12β-diacetyl-protopanaxadiol (37)

To a solution of compound 20(S)-PPD (150.0 mg, 0.33 mmol) in pyridine (1.0 mL) was added acetic anhydride (1.2 mL) and DMAP (1.8 mg, 0.02 mmol) at room temperature. After being stirred for 4 h, the reaction mixture was diluted with EtOAc, and washed with 5% HCl aqueous solution and brine in sequence. The organic phases were combined, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 10:90) to give compound 37 (86% yield) as a white powder, 1H NMR (400 MHz, CDCl3) δ 4.49 (1H, dd, J = 11.5, 4.7 Hz, H-3), 4.74 (1H, td, J = 10.6, 4.6 Hz, H-12), 5.16 (1H, t, J = 7.1 Hz, H-24), 1.71 (3H, s, H-26), 1.64 (3H, s, H-27), 1.13 (3H, s), 1.01 (3H, s), 0.95 (3H, s), 0.88 (3H, s), 0.85 (6H, overlap), 2.04 (6H, s, H-2′, H-2″); HRMS (ESI+) m/z calcd for C34H56O5Na 567.4020, found 567.3980 (M + Na+).

Procedure for the synthesis of compounds 38–40

To the solution of compound 37 (24.0 mg, 0.04 mmol) in ethanol-water (15:1, v/v, 6.4 mL) was added KMnO4 (8.2 mg, 0.05 mmol) at −40 °C and the reaction was stirred for 6 h at the same temperature before it was quenched by the addition of 10% Na2S2O3 aqueous solution. The mixture was extracted with EtOAc and the combined organic layers were washed with 5% HCl and brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude was dissolved in methanol (3.0 mL), followed by the addition 10% NaOH aqueous solution (1.0 mL). The reaction was heated to reflux and stirred for 2 h. After cooling to room temperature, the solution was diluted with EtOAc and washed with 5% HCl aqueous solution and brine in sequence. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (methanol-acetone-petroleum ether, 7.5:15:85) to give compounds 38 and 39.

The mixture of compounds 38 and 39 were dissolved in methanol-water (3:2, v/v, 1.0 mL) and followed by the addition of NaIO4 (21.4 mg, 0.10 mmol). The reaction was stirred at room temperature overnight. The reaction was quenched with 10% Na2S2O3 and extracted with EtOAc. The combined organic phases were washed with brine and dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (acetone-petroleum ether, 10:90) to give compound 40.

20S-24,25-dihydroxy-protopanaxadiol (38)

White powder, 52% yield; 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.2, 5.1 Hz, H-3), 3.58 (1H, td, J = 10.4, 5.0 Hz, H-12), 3.33 (1H, d, J = 9.6 Hz, H-24), 1.22 (3H, s), 1.17 (6H, s), 0.99 (3H, s), 0.98 (3H, s), 0.88 (6H, s), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 39.0 (CH2, C-1), 27.3 (CH2, C-2), 78.9 (CH, C-3), 39.7 (C, C-4), 55.8 (CH, C-5), 18.3 (CH2, C-6), 34.8 (CH2, C-7), 38.9 (C, C-8), 50.2 (CH, C-9), 37.1 (C, C-10), 31.1 (CH2, C-11), 71.2 (CH, C-12), 47.8 (CH, C-13), 51.6 (C, C-14), 31.1 (CH2, C-15), 25.6 (CH2, C-16), 53.1 (CH, C-17), 15.7 (CH3, C-18), 15.4 (CH3, C-19), 73.4 (C, C-20), 26.6 (CH3, C-21), 32.9 (CH2, C-22), 25.3 (CH2, C-22), 79.6 (CH, C-24), 73.1 (C, C-25), 26.6 (CH3, C-26), 23.5 (CH3, C-27), 28.0 (CH3, C-28), 16.2 (CH3, C-29), 16.8 (CH3, C-30); HRMS (ESI) m/z calcd for C31H55O7 539.3953, found 539.3934 (M + HCOO).

20S-24,25-dihydroxy-protopanaxadiol (39)

White powder, 42% yield; 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.2, 5.0 Hz, H-3), 3.59 (1H, td, J = 10.3, 5.1 Hz, H-12), 3.45 (1H, d, J = 10.3 Hz, H-24), 1.23 (3H, s), 1.18 (6H, s), 0.99 (3H, s), 0.98 (3H, s), 0.88 (6H, s), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 39.1 (CH2, C-1), 27.5 (CH2, C-2), 78.7 (CH, C-3), 39.8 (C, C-4), 56.0 (CH, C-5), 18.4 (CH2, C-6), 34.9 (CH2, C-7), 39.1 (C, C-8), 50.3 (CH, C-9), 37.2 (C, C-10), 31.1 (CH2, C-11), 71.5 (CH, C-12), 47.9 (CH, C-13), 51.8 (C, C-14), 31.5 (CH2, C-15), 26.7 (CH2, C-16), 53.9 (CH, C-17), 15.8 (CH3, C-18), 15.5 (CH3, C-19), 74.1 (C, C-20), 27.2 (CH3, C-21), 31.6 (CH2, C-22), 25.6 (CH2, C-22), 79.0 (CH, C-24), 73.4 (C, C-25), 26.5 (CH3, C-26), 23.7 (CH3, C-27), 28.2 (CH3, C-28), 16.3 (CH3, C-29), 17.0 (CH3, C-30); HRMS (ESI) m/z calcd for C31H55O7 539.3953, found 539.3914 (M + HCOO).

20S-epoxy-3β,12β,24-trihydroxy-dammarane (40)

White powder, 82% yield; 1H NMR (400 MHz, CDCl3) δ 3.19 (1H, dd, J = 11.3, 4.9 Hz, H-3), 3.78 (1H, td, J = 10.6, 5.6 Hz, H-12), 5.55 (1H, d, J = 6.4 Hz, H-24), 1.29 (3H, s), 0.98 (6H, s), 0.91 (3H, s), 0.87 (3H, s), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 38.9 (CH2, C-1), 27.4 (CH2, C-2), 78.8 (CH, C-3), 40.0 (C, C-4), 55.7 (CH, C-5), 18.2 (CH2, C-6), 34.6 (CH2, C-7), 38.9 (C, C-8), 49.7 (CH, C-9), 37.2 (C, C-10), 30.2 (CH2, C-11), 73.8 (CH, C-12), 47.7 (CH, C-13), 50.0 (C, C-14), 31.9 (CH2, C-15), 23.7 (CH2, C-16), 52.8 (CH, C-17), 16.0 (CH3, C-18), 15.9 (CH3, C-19), 87.6 (C, C-20), 37.2 (CH2, C-22), 28.9 (CH2, C-23), 102.2 (CH, C-24), 28.1 (CH3, C-28), 15.4 (CH3, C-29), 16.9 (CH3, C-30); HRMS (ESI+) m/z calcd for C27H46O4Na 457.3288, found 457.3310 (M + Na+).

Procedure for the synthesis of compounds 41–43

A suspension of 10% Pd/C (12.0 mg) and compound 37 (116.0 mg, 0.21 mmol) in ethanol (3.0 mL) was stirred at room temperature under hydrogen atmosphere. After being stirred for 12 h, the suspension was filtered through a Celite pad and the pad was washed with CH2Cl2. The filtrate was concentrated and purified by column chromatography on silica gel (acetone- petroleum ether, 10:90) to give compound 41.

To a solution of compound 41 in pyridine (2.0 mL) was added POCl3 (40.8 μL, 1.32 mmol) at 0 °C. After 20 min, the mixture was heated to 40 °C and stirred overnight. The solution was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The crude was dissolved in methanol and followed by the addition of 10% NaOH aqueous solution (1.0 mL). The mixture refluxed for 2 h. After cooling to room temperature, the solution was diluted with EtOAc and washed with 5% HCl aqueous solution and brine in sequence. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (EtOAc-petroleum ether, 4:96) to give compounds 42 and 43.

20S-24,25-dihydro-3β,12β-diacetyl -protopanaxadiol (41)

White powder, 87% yield; 1H NMR (400 MHz, CDCl3) δ 4.49 (1H, dd, J = 11.5, 4.6 Hz, H-3), 4.74 (1H, td, J = 10.9, 5.1 Hz, H-12), 1.11 (3H, s), 1.01 (3H, s), 0.95 (3H, s), 0.91 (3H, s), 0.89 (6H, s), 0.85 (6H, s), 2.04 (6H, s, H-2′, H-2″); 13C NMR (100 MHz, CDCl3) δ 38.5 (CH2, C-1), 23.5 (CH2, C-2), 80.5 (CH, C-3), 37.8 (C, C-4), 55.8 (CH, C-5), 18.1 (CH2, C-6), 34.5 (CH2, C-7), 39.7 (C, C-8), 49.9 (CH, C-9), 37.0 (C, C-10), 28.2 (CH2, C-11), 76.5 (C, C-12), 44.8 (CH, C-13), 52.6 (C, C-14), 31.5 (CH2, C-15), 27.2 (CH2, C-16), 52.7 (CH, C-17), 16.2 (CH3, C-18), 15.5 (CH3, C-19), 73.7 (C, C-20), 26.3 (CH3, C-21), 36.4 (CH2, C-22), 21.3 (CH2, C-23), 40.0 (CH2, C-24), 28.1 (CH, C-25), 22.7 (CH3, C-26), 22.7 (CH3, C-27), 27.9 (CH3, C-28), 16.4 (CH3, C-29), 17.3 (CH3, C-30), 170.8 (C, C-1′), 21.5 (CH3, C-2′), 170.0 (C, C-1″), 21.2 (CH3, C-2″); HRMS (ESI+) m/z calcd for C34H58O5Na 569.4176, found 569.4189 (M + Na+).

20S-20,21-ene-24,25-dihydro-protopanaxadiol (42)

White powder, 16% yield; 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.2, 5.0 Hz, H-3), 3.59 (1H, td, J = 10.3, 5.2 Hz, H-12), 5.01 (1H, br s, H-21a), 4.77 (1H, br s, H-21b), 1.18 (3H, s), 0.99 (3H, s), 0.98 (3H, s), 0.88 (12H, overlap), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 39.0 (CH2, C-1), 27.4 (CH2, C-2), 78.8 (CH, C-3), 40.1 (C, C-4), 55.9 (CH, C-5), 18.3 (CH2, C-6), 35.0 (CH2, C-7), 38.9 (C, C-8), 50.4 (CH, C-9), 37.2 (C, C-10), 30.9 (CH2, C-11), 73.3 (C, C-12), 48.1 (CH, C-13), 50.8 (C, C-14), 32.3 (CH2, C-15), 26.0 (CH2, C-16), 50.9 (CH, C-17), 16.2 (CH3, C-18), 15.7 (CH3, C-19), 156.2 (C, C-20), 109.0 (CH2, C-21), 32.9 (CH2, C-22), 29.1 (CH2, C-23), 39.0 (CH2, C-24), 28.0 (CH, C-25), 22.7 (CH3, C-26), 22.6 (CH3, C-27), 28.0 (CH3, C-28), 15.4 (CH3, C-29), 16.7 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H53O2 445.4040, found 445.4037 (M + H+).

20S-E-20,22-ene-24,25-dihydro-protopanaxadiol (43)

White powder, 43% yield; 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.3, 5.0 Hz, H-3), 3.74 (1H, td, J = 10.6, 5.2 Hz, H-12), 1.64 (3H, s, H-21), 5.42 (1H, t, J = 7.1 Hz, H-22), 1.02 (3H, s), 0.98 (3H, s), 0.89 (3H, s), 0.88 (9H, overlap), 0.86 (3H, s), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 38.6 (CH2, C-1), 27.4 (CH2, C-2), 78.8 (CH, C-3), 39.0 (C, C-4), 55.9 (CH, C-5), 18.3 (CH2, C-6), 35.0 (CH2, C-7), 40.1 (C, C-8), 50.1 (CH, C-9), 37.2 (C, C-10), 30.4 (CH2, C-11), 73.4 (C, C-12), 50.3 (CH, C-13), 50.5 (C, C-14), 32.5 (CH2, C-15), 27.3 (CH2, C-16), 50.2 (CH, C-17), 16.2 (CH3, C-18), 15.7 (CH3, C-19), 140.3 (C, C-20), 12.4 (CH3, C-21), 126.4 (CH, C-22), 25.8 (CH2, C-23), 29.0 (CH2, C-24), 27.7 (CH, C-25), 22.6 (CH3, C-26), 22.4 (CH3, C-27), 28.0 (CH3, C-28), 15.4 (CH3, C-29), 16.8 (CH3, C-30); HRMS (ESI+) m/z calcd for C30H53O2 445.4040, found 445.4031 (M + H+).

20-oxo-protopanaxadiol (44)

To a stirred solution of compound 43 (26.6 mg, 0.06 mmol) in 2.0 mL of methanol-water (3:2) was added NaIO4 (29.7 mg, 0.14 mmol) and OsO4 (35 μL, 2% aqueous solution, 0.002 mmol) at ambient temperature. After stirred for 12 h, the reaction was quenched with saturated aqueous Na2S2O3 and extracted with EtOAc. The organic extracts were combined, dried over anhydrous sodium sulfate, filtered. After removal of the solvent under vacuum, the residue was purified by column chromatography on silica gel (acetone-petroleum ether, 10:90) to give compound 44 (61% yield) as a white powder, 1H NMR (400 MHz, CDCl3) δ 3.20 (1H, dd, J = 11.4, 5.0 Hz, H-3), 3.48 (1H, td, J = 10.7, 5.1 Hz, H-12), 2.86 (1H, td, J = 11.1, 5.6 Hz, H-17), 2.23 (3H, s, H-21), 1.02 (3H, s), 0.98 (3H, s), 0.89 (3H, s), 0.88 (3H, s), 0.78 (3H, s); 13C NMR (100 MHz, CDCl3) δ 39.0 (CH2, C-1), 27.4 (CH2, C-2), 78.8 (CH, C-3), 38.9 (C, C-4), 55.9 (CH, C-5), 18.2 (CH2, C-6), 35.1 (CH2, C-7), 39.8 (C, C-8), 50.6 (CH, C-9), 37.2 (C, C-10), 31.9 (CH2, C-11), 71.7 (C, C-12), 50.2 (CH, C-13), 51.2 (C, C-14), 32.5 (CH2, C-15), 26.8 (CH2, C-16), 53.2 (CH, C-17), 16.3 (CH3, C-18), 15.7 (CH3, C-19), 214.7 (C, C-20), 29.4 (CH3, C-21), 28.0 (CH3, C-28), 15.4 (CH3, C-29), 17.0 (CH3, C-30); HRMS (ESI+) m/z calcd for C24 H40O3Na 399.2870, found 399.2832 (M + Na+).

Biology

In vitro inhibition activity of α-glucosidase

The α-glucosidase inhibition activity was investigated by a spectrophotometric method as previous researches [12, 1416, 18]. Acarbose (Bayer Healthcare Co Ltd, Beijing, China) was utilized as a positive control and was dissolved in phosphate buffer (PB, 0.1 mM, pH = 6.8). Test samples dissolved in methanol-PB (1:1, v/v, 20 μL) and p-Nitrophenyl-α-D-glucopyranoside (20 μL, 5.0 mM, p-NPG) dissolved in PB (in triplicate) were added to a 96-well plate and incubated at 37 °C for 5 min. Then α-glucosidase dissolved in PB (2.0 U/mL, 20 μL, Shanghai yuanye Bio-Technology Co Ltd, China) was added to each well as a substrate. After incubation for 15 min at 37 °C, the reaction was terminated with Na2CO3 solution (40 μL, 0.5 mM). Another preincubation for 5 min, the absorbance was measured at 405 nm via a Bio-Rad 680 microplate reader (Hercules, CA, USA). The system using PB replace test compounds was used as control. The mixtures’ reaction without α-glucosidase was used as blank.

The α-glucosidase inhibitory rate % = [(ΔODcontrol − ΔODcontrol blank) − (ΔODsample − ΔODsample blank)]/(ΔODcontrol − ΔODcontrol blank). IC50 values were tested and calculated through nonlinear regression using Graphpad prism 8 software, which concentration of sample resulting in 50% inhibition.

In vitro inhibition activity of PTP1B

The PTP1B inhibition assay was investigated by the method as previous reports [14, 16, 18]. Working buffer containing MOPS (34.5 mM), DTT (1.9 mM), EDTA·4Na (0.67 mM), BSA (2.0 mg/mL), and NaCl (2.1 mM) in deionized water was prepared before the assay. Suramin sodium was utilized as a positive control dissolved in DMSO. Working buffer (70 µL), test samples dissolved in DMSO (10 µL) and PTP1B dissolved in working buffer (10 µL, 4.9 mg/L) were added to a 96-well plate and incubated at 37 °C for 15 min. Then the substrate in working buffer (10 µL, 100 mM, p-NPP) was added to each well. After incubation for 30 min, the reaction was stopped by adding 100 μL of Na2CO3 solution (0.1 mM). The absorbance was measured at 405 nm via a Bio-Rad 680 microplate reader (Hercules, CA, USA). The system using DMSO replace test compounds was used as control. The mixtures’ reaction without PTP1B was used as blank. The PTP1B inhibitory rate and IC50 values of compounds were calculated using the same method as described above.

Enzyme kinetic studies of compounds 26 and 42 for α-glucosidase and PTP1B

The enzyme kinetics of α-glucosidase and PTP1B inhibition for compounds 26 and 42 were investigated according to experiments as described above. For α-glucosidase, enzymatic reactions at four different tested concentrations of compound 26 (0, 440, 470, and 500 μM) were evaluated by monitoring the effects of three different substrate concentrations (5.0, 2.5, and 1.0 mM). And for PTP1B, the inhibitory modes of compounds 26 and 42 were measured using three different concentrations of p-NPP (25, 50, 100 mM), and four different concentrations of tested compounds (compound 26: 0, 240, 270, 300 μM; compound 42: 0, 100, 200, 400 μM) to obtain Lineweaver−Burk double reciprocal plots. The inhibition constants (Ki) were calculated by the x-axis value of intersection of Dixon plot.

Supplementary information

Supplementary Material (6.8MB, pdf)

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81773612), the Yunnan Science Fund for Excellent Young Scholars (2019FI017), the Youth Innovation Promotion Association, CAS (2020386), and the Reserve Talents of Young and Middle-aged Academic and Technical Leaders in Yunnan Province (TZLi).

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1007/s00044-021-02836-0.

References

  • 1.Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. doi: 10.1038/nrendo.2017.151. [DOI] [PubMed] [Google Scholar]
  • 2.Andreoulakis E, Hyphantis T, Kandylis D, Iacovides A. Depression in diabetes mellitus: a comprehensive review. Hippokratia. 2012;16:205–14. [PMC free article] [PubMed] [Google Scholar]
  • 3.Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64. doi: 10.2522/ptj.20080020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Trinh BTD, Staerk D, Jäger AK. Screening for potential α-glucosidase and α-amylase inhibitory constituents from selected Vietnamese plants used to treat type 2 diabetes. J Ethnopharmacol. 2016;186:189–95. doi: 10.1016/j.jep.2016.03.060. [DOI] [PubMed] [Google Scholar]
  • 5.Quan NV, Tran HD, Xuan TD, Ahmad A, Dat TD, Khanh TD, et al. Momilactones A and B are α-amylase and α-glucosidase inhibitors. Molecules. 2019;24:482–94. doi: 10.3390/molecules24030482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ayinampudi SR, Domala R, Merugu R, Bathula S, Janaswamy MR. New icetexane diterpenes with intestinal α-glucosidase inhibitory and free-radical scavenging activity isolated from Premna tomentosa roots. Fitoterapia. 2012;83:88–92. doi: 10.1016/j.fitote.2011.09.018. [DOI] [PubMed] [Google Scholar]
  • 7.Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discovery. 2002;1:696–709. doi: 10.1038/nrd895. [DOI] [PubMed] [Google Scholar]
  • 8.Ukkola O, Santaniemi M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J Intern Med. 2002;251:467–75. doi: 10.1046/j.1365-2796.2002.00992.x. [DOI] [PubMed] [Google Scholar]
  • 9.Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 2000;20:5479–89. doi: 10.1128/MCB.20.15.5479-5489.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. Curr Opin Chem Biol. 2001;5:416–23. doi: 10.1016/s1367-5931(00)00223-4. [DOI] [PubMed] [Google Scholar]
  • 11.Khalaf RA. Exploring natural products as a source for antidiabetic lead compounds and possible lead optimization. Curr Top Med Chem. 2016;16:2549–61. doi: 10.2174/1568026616666160414123602. [DOI] [PubMed] [Google Scholar]
  • 12.Mukherjee PK, Kar A, Banerjee S, Katiyar CK. Antidiabetic natural products. Annu Rep Med Chem. 2020;55:373–409. doi: 10.1016/bs.armc.2020.06.002. [DOI] [Google Scholar]
  • 13.He XF, Chen JJ, Li TZ, Hu J, Zhang XM, Geng CA. Diarylheptanoid-chalcone hybrids with PTP1B and alpha-glucosidase dual inhibition from Alpinia katsumadai. Bioorg Chem. 2021;108:104683. doi: 10.1016/j.bioorg.2021.104683. [DOI] [PubMed] [Google Scholar]
  • 14.He XF, Chen JJ, Li TZ, Hu J, Zhang XK, Guo YQ, et al. Tsaokols A and B, unusual flavanol-monoterpenoid hybrids as alpha-glucosidase inhibitors from Amomum tsao-ko. Chin Chem Lett. 2021;32:1202–5. doi: 10.1016/j.cclet.2020.08.050. [DOI] [Google Scholar]
  • 15.He XF, Chen JJ, Li TZ, Hu J, Huang XY, Zhang XM, et al. Diarylheptanoid-flavanone hybrids as multiple-target antidiabetic agents from Alpinia katsumadai. Chin J Chem. 2021;39:3051–63. doi: 10.1002/cjoc.202100469. [DOI] [Google Scholar]
  • 16.He XF, Chen JJ, Huang XY, Hu J, Zhang XK, Guo YQ, et al. The antidiabetic potency of Amomum tsao-ko and its active flavanols, as PTP1B selective and alpha-glucosidase dual inhibitors. Ind Crops Prod. 2021;160:112908. doi: 10.1016/j.indcrop.2020.112908. [DOI] [Google Scholar]
  • 17.He XF, Zhang XK, Geng CA, Hu J, Zhang XM, Guo YQ, et al. Tsaokopyranols A-M, 2,6-epoxydiarylheptanoids from Amomum tsao-ko and their alpha-glucosidase inhibitory activity. Bioorg Chem. 2020;96:103638. doi: 10.1016/j.bioorg.2020.103638. [DOI] [PubMed] [Google Scholar]
  • 18.He XF, Chen JJ, Li TZ, Zhang XK, Guo YQ, Zhang XM, et al. Nineteen new flavanol-fatty alcohol hybrids with alpha-glucosidase and PTP1B dual inhibition: one unusual type of antidiabetic constituent from Amomum tsao-ko. J Agri Food Chem. 2020;68:11434–48. doi: 10.1021/acs.jafc.0c04615. [DOI] [PubMed] [Google Scholar]
  • 19.Deng ZT, Chen JJ, Geng CA. ent-Labdane and ent-kaurane diterpenoids from Chelonopsis odontochila with alpha-glucosidase inhibitory activity. Bioorg Chem. 2020;95:103571. doi: 10.1016/j.bioorg.2020.103571. [DOI] [PubMed] [Google Scholar]
  • 20.Zhang CC, Geng CA, Huang XY, Zhang XM, Chen JJ. Antidiabetic stilbenes from peony seeds with PTP1B, alpha-glucosidase, and DPPIV inhibitory activities. J Agric Food Chem. 2019;67:6765–72. doi: 10.1021/acs.jafc.9b01193. [DOI] [PubMed] [Google Scholar]
  • 21.Deng ZT, Geng CA, Yang TH, Xiang CL, Chen JJ, Chepraecoxins A-G. ent-kaurane diterpenoids with alpha-glucosidase inhibitory activities from Chelonopsis praecox. Fitoterapia. 2019;132:60–7. doi: 10.1016/j.fitote.2018.11.014. [DOI] [PubMed] [Google Scholar]
  • 22.Yan DX, Geng CA, Yang TH, Huang XY, Li TZ, Gao Z, et al. LC-MS guided isolation of diterpenoids from Sapium insigne with alpha-glucosidase inhibitory activities. Fitoterapia. 2018;128:57–65. doi: 10.1016/j.fitote.2018.03.009. [DOI] [PubMed] [Google Scholar]
  • 23.Sun H, Tan J, Lv W, Li J, Wu J, Xu J, et al. Hypoglycemic triterpenoid glycosides from Cyclocarya paliurus (Sweet TeaTree) Bioorg Chem. 2020;95:103493. doi: 10.1016/j.bioorg.2019.103493. [DOI] [PubMed] [Google Scholar]
  • 24.Li C, Deng S, Liu W, Zhou D, Huang Y, Liang C, et al. α -Glucosidase inhibitory and anti-inflammatory activities of dammarane triterpenoids from the leaves of Cyclocarya paliurus. Bioorg Chem. 2021;111:104847. doi: 10.1016/j.bioorg.2021.104847. [DOI] [PubMed] [Google Scholar]
  • 25.Kohyama A, Yokoyama R, Dibwe DF, El-Mekkawy S, Meselhy R, Awale S, et al. Synthesis of guggulsterone derivatives as potential anti-austerity agents against PANC-1 human pancreatic cancer cells. Bioorg Med Chem Lett. 2020;30:126964. doi: 10.1016/j.bmcl.2020.126964. [DOI] [PubMed] [Google Scholar]
  • 26.Mo XB, Morgan TDR, Ang HT, Hall DG. Scope and mechanism of a true organocatalytic Beckmann rearrangement with a boronic acid/perfluoropinacol system under ambient conditions. J Am Chem Soc. 2018;140:5264–71. doi: 10.1021/jacs.8b01618. [DOI] [PubMed] [Google Scholar]
  • 27.Wu ZJ, Li Y, Cai Y, Yuan JY, Yuan CY. A novel necroptosis inhibitor–necrostatin-21 and its SAR study. Bioorg Med Chem Lett. 2013;23:4903–06. doi: 10.1016/j.bmcl.2013.06.073. [DOI] [PubMed] [Google Scholar]
  • 28.Kaur R, Khan S, Chib R, Kaur T, Sharma PR, Singh J, et al. A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid. Eur J Med Chem. 2011;46:1356–66. doi: 10.1016/j.ejmech.2011.01.061. [DOI] [PubMed] [Google Scholar]
  • 29.Wang H, Yu F, Peng YY, Wang Q, Han X, Xu RY, et al. Synthesis and biological evaluation of ring A and/or C expansion and opening echinocystic acid derivatives for anti-HCV entry inhibitors. Eur J Med Chem. 2015;102:594–9. doi: 10.1016/j.ejmech.2015.08.034. [DOI] [PubMed] [Google Scholar]
  • 30.Malika IO, Khalil H, Luc R. Synthesis of 12-oxa, 12-aza and 12-thia cholanetriols. Steroids. 2011;76:324–30. doi: 10.1016/j.steroids.2010.12.003. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material (6.8MB, pdf)

Articles from Medicinal Chemistry Research are provided here courtesy of Nature Publishing Group

RESOURCES